Biotelemetry 10-K 26 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 24, 2014	Jun. 28, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'BioTelemetry, Inc.	'	'
Entity Central Index Key	'0001574774	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$86,455,267
Entity Common Stock, Shares Outstanding	'	26,036,418	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$22,151	$18,298
Accounts receivable-patient services, net of allowance for doubtful accounts of $7,555 and $7,532 at December 31, 2013 and 2012, respectively	11,437	13,792
Other accounts receivable, net of allowance for doubtful accounts of $85 at December 31, 2013 and 2012, respectively	5,680	6,515
Inventory	2,554	2,894
Prepaid expenses and other current assets	2,433	1,923
Total current assets	44,255	43,422
Property and equipment, net	18,779	19,851
Intangible assets, net	7,312	9,664
Goodwill	16,469	16,446
Other assets	731	627
Total assets	87,546	90,010
Current liabilities:	'	'
Accounts payable	8,718	6,349
Accrued liabilities	8,190	9,946
Current portion of capital leases	187	'
Deferred revenue	1,945	2,195
Total current liabilities	19,040	18,490
Deferred tax liability	767	866
Long term portion of capital leases	469	'
Deferred rent	441	656
Total liabilities	20,717	20,012
Shareholders' equity	'	'
Common stock-$.001 par value as of December 31, 2013 and 2012; 200,000,000 shares authorized as of December 31, 2013 and 2012; 25,812,754 and 25,189,340 shares issued and outstanding at December 31, 2013 and 2012, respectively	26	25
Paid-in capital	260,597	256,448
Accumulated deficit	-193,794	-186,475
Total shareholders' equity	66,829	69,998
Total liabilities and shareholders' equity	$87,546	$90,010

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
CONSOLIDATED BALANCE SHEETS	'	'
Accounts receivable-patient services, allowance for doubtful accounts (in dollars)	$7,555	$7,532
Other accounts receivable, allowance for doubtful accounts (in dollars)	$85	$85
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	25,812,754	25,189,340
Common stock, shares outstanding	25,812,754	25,189,340

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Patient services	$100,386	$93,640	$106,853
Research services	20,329	8,333	1,079
Product	8,786	9,521	11,090
Total revenues	129,501	111,494	119,022
Cost of revenue:	'	'	'
Patient services	34,179	36,793	42,258
Research services	11,317	3,726	571
Product	4,935	5,074	6,247
Total cost of revenues:	50,431	45,593	49,076
Gross profit	79,070	65,901	69,946
Operating expenses:	'	'	'
General and administrative	36,569	32,644	35,011
Sales and marketing	26,275	25,604	27,821
Bad debt expense	7,787	11,912	12,080
Research and development	7,338	4,664	5,698
Integration, restructuring and other charges	7,982	4,236	4,659
Goodwill impairment	'	'	45,999
Total operating expenses	85,951	79,060	131,268
Loss from operations	-6,881	-13,159	-61,322
Other (loss) income (net)	-223	52	144
Loss before income taxes	-7,104	-13,107	-61,178
(Provision) benefit for income taxes	-215	905	-244
Net loss	-7,319	-12,202	-61,422
Net loss per common share:	'	'	'
Basic and diluted (in dollars per share)	($0.29)	($0.49)	($2.51)
Weighted average number of common shares outstanding:	'	'	'
Basic and diluted (in shares)	25,543,646	24,933,656	24,425,318
Unrealized gains/(losses) on securities:	'	'	'
Unrealized holding gains/(losses) arising during the period	'	16	-24
Comprehensive loss	($7,319)	($12,186)	($61,446)

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating activities	'	'	'
Net loss	($7,319)	($12,202)	($61,422)
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'	'
Provision for doubtful accounts	7,787	11,912	12,080
Depreciation	9,978	8,037	10,913
Decrease in deferred rent	-215	-198	-303
Deferred income tax (benefit) expense	53	-1,033	13
Stock-based compensation	3,303	3,747	4,006
Amortization of intangibles	2,340	1,341	1,219
Amortization of investment premium	'	268	561
Goodwill impairment	'	'	45,999
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-4,597	-3,635	-6,653
Inventory	340	-885	-548
Prepaid expenses and other assets	-637	691	3,661
Accounts payable	2,369	552	-3,033
Accrued and other liabilities	-2,143	-2,852	-1,463
Net cash provided by operating activities	11,259	5,743	5,030
Investing activities	'	'	'
Acquisition of businesses, net of cash acquired	'	-28,155	'
Purchases of property and equipment	-8,169	-5,962	-3,954
Purchases of short-term available-for-sale investments	'	-11,935	-49,657
Sale or maturity of short-term available-for-sale investments	'	39,636	47,898
Net cash used in investing activities	-8,169	-6,416	-5,713
Financing activities	'	'	'
Proceeds from the exercise of employee stock options and employee stock purchase plan contributions	847	440	509
Principal payments on capital lease obligations	-84	'	'
Net cash provided by financing activities	763	440	509
Net increase (decrease) in cash and cash equivalents	3,853	-233	-174
Cash and cash equivalents - beginning of period	18,298	18,531	18,705
Cash and cash equivalents - end of period	22,151	18,298	18,531
Supplemental disclosure of cash flow information	'	'	'
Cash paid for interest	132	295	'
Cash paid for taxes	112	135	171
Capital lease obligations	$737	$0	$0

CONSOLIDATED_STATEMENTS_OF_SHA

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $)	Total	Common Stock	Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2010	$134,928	$24	$247,747	$8	($112,851)
Balance (in shares) at Dec. 31, 2010	'	24,251,170	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'
Exercise of stock options and purchase of shares related to the employee stock purchase plan	515	'	515	'	'
Exercise of stock options and purchase of shares related to the employee stock purchase plan (in shares)	'	170,607	'	'	'
Stock based compensation	4,000	1	3,999	'	'
Stock based compensation (in shares)	'	112,824	'	'	'
Net loss	-61,422	'	'	'	-61,422
Changes in unrealized gain on available-for-sale investments	-24	'	'	-24	'
Balance at Dec. 31, 2011	77,997	25	252,261	-16	-174,273
Balance (in shares) at Dec. 31, 2011	'	24,534,601	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'
Exercise of stock options and purchase of shares related to the employee stock purchase plan	440	'	440	'	'
Exercise of stock options and purchase of shares related to the employee stock purchase plan (in shares)	'	194,878	'	'	'
Stock based compensation	3,747	'	3,747	'	'
Stock based compensation (in shares)	'	459,861	'	'	'
Net loss	-12,202	'	'	'	-12,202
Changes in unrealized gain on available-for-sale investments	16	'	'	16	'
Balance at Dec. 31, 2012	69,998	25	256,448	'	-186,475
Balance (in shares) at Dec. 31, 2012	'	25,189,340	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'
Exercise of stock options and purchase of shares related to the employee stock purchase plan	847	1	846	'	'
Exercise of stock options and purchase of shares related to the employee stock purchase plan (in shares)	'	348,681	'	'	'
Stock based compensation	3,303	'	3,303	'	'
Stock based compensation (in shares)	'	274,733	'	'	'
Net loss	-7,319	'	'	'	-7,319
Balance at Dec. 31, 2013	$66,829	$26	$260,597	'	($193,794)
Balance (in shares) at Dec. 31, 2013	'	25,812,754	'	'	'

Organization_and_Description_o

Organization and Description of Business	12 Months Ended
	Dec. 31, 2013
Organization and Description of Business	'
Organization and Description of Business	'
	1. Organization and Description of Business
	BioTelemetry, Inc. (the "Company," "BioTelemetry," "we" or "us"), a Delaware corporation, was formerly known as CardioNet, Inc. CardioNet, Inc. was reorganized under a holding company structure with the new name BioTelemetry, Inc. effective July 31, 2013. On August 1, 2013, the Company continued trading on NASDAQ under the symbol "BEAT".
	BioTelemetry, Inc. provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. Since the Company became focused on cardiac monitoring in 1999, the Company has developed a proprietary integrated patient management platform that incorporates a wireless data transmission network, Food and Drug Administration ("FDA") cleared algorithms and medical devices, and 24-hour digital monitoring service centers.
	The Company operates under three segments: patient services, product and research services. The patient services segment is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. The Company provides cardiologists and electrophysiologists who prefer to use a single source of cardiac monitoring services with a full spectrum of solutions, ranging from the differentiated Mobile Cardiac Outpatient TelemetryTM ("MCOT™") service to wEvent, event, Holter, Pacemaker and International normalized ratio ("INR") monitoring. INR monitoring is a measurement of blood coagulation in the circulatory system and is prescribed for patients on long term anticoagulation therapy. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The research services segment is engaged in central core laboratory services providing cardiac monitoring, scientific consulting and data management services for drug and medical device trials.
	In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. ("Cardiocore"). Cardiocore is a central core laboratory that provides cardiac monitoring services for drug and medical treatment trials. Cardiocore's primary customers are pharmaceutical companies and contract research organizations. The acquisition gave the Company access to industry expertise, an established operating structure and a substantial footprint in the core lab industry. Cardiocore is included in the Company's research services segment.
	In February 2012, the Company completed the acquisition of ECG Scanning & Medical Services, Inc. ("ECG Scanning"). Similar to the Company's core patient services business, ECG Scanning was engaged in providing cardiac monitoring services to general practitioners, internal medicine specialists, cardiologists and hospital cardiac care departments. The acquisition gave the Company access to established customer relationships and provided cost synergies. ECG Scanning is included in the Company's patient services segment.
	On December 21, 2010, the Company completed the acquisition of Biotel Inc. ("Biotel"), and its wholly owned subsidiaries, Braemar, Inc. ("Braemar") and Agility Centralized Research Services, Inc. ("Agility"). Braemar develops, manufactures, and markets cardiac monitoring devices to healthcare companies, clinics and hospitals. Agility is a central core laboratory that provides cardiac monitoring service to medical device companies who are seeking FDA approval of their products. This acquisition provided access to an established customer base and diversified the Company's revenue by adding manufacturing and core laboratory services to its portfolio. Braemar is included in the Company's product segment, whereas Agility was repositioned during 2012 into the Company's research services segment.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates.
	Fair Value of Financial Instruments
	The Company's financial instruments consist mainly of cash and cash equivalents, accounts receivable, other current assets, accounts payable, deferred revenue and other current liabilities. The carrying value of these financial instruments approximates their fair value because of their short-term nature. The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties.
	Cash and Cash Equivalents
	Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash and have insignificant interest rate risk.
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable related to the patient services segment are recorded at the time revenue is recognized, net of contractual allowances, and are presented on the balance sheet net of allowance for doubtful accounts. The ultimate collection of accounts receivable may not be known for several months after services have been provided and billed. The Company records bad debt expense based on the aging of receivables using historical company specific data. The percentages and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections, and the aging of specific receivables. Because of continuing changes in the health care industry and third party reimbursement, it is possible that the Company's estimates of collectability could change, which could have a material impact on the Company's operations and cash flows.
	Accounts receivable related to the product and research services segments are recorded at the time revenue is recognized, or when the services or products are billable, net of discounts. The Company estimates allowance for doubtful accounts on a specific account basis, and considers several factors in its analysis including customer specific information and aging of the account.
	The Company writes off receivables when the likelihood for collection is remote and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The Company performs write-offs on a monthly basis. In the patient services segment, the Company wrote off $7,919 and $14,184 of receivables for the years ended December 31, 2013 and 2012, respectively. The impact was a reduction of gross receivables and a reduction in the allowance for doubtful accounts. Additionally, the Company recorded bad debt expense of $7,787, $11,912 and $12,080 for the years ended December 31, 2013, 2012 and 2011, respectively. Based on collection experience, unfavorable adjustments of $1,480 and $6,343 were made to accounts receivable in 2013 and 2012, respectively, related to prior years accounts receivable. There were no write-offs in the product and research services segments.
	Concentrations of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents with high quality financial institutions to mitigate this risk. The Company performs ongoing credit evaluations of its customers and generally does not require collateral. The Company records an allowance for doubtful accounts in accordance with the procedures described above. Past-due amounts are written off against the allowance for doubtful accounts when collections are believed to be unlikely and all collection efforts have ceased.
	At December 31, 2013, 2012 and 2011, one customer, Medicare, accounted for 18%, 20% and 19%, respectively, of the Company's net accounts receivable.
	Inventory
	Inventory is valued at the lower of cost (using first-in, first-out cost method) or market (net realizable value or replacement cost). Company management periodically reviews inventory for specific future usage, and estimates of impairment of individual inventory items are recorded to reduce inventory to the lower of cost or market.
	Property and Equipment
	Property and equipment is recorded at cost. Depreciation is recorded over the estimated useful life of each class of depreciable assets, and is computed using the straight-line method. Leasehold improvements are amortized over the shorter of the estimated asset life or term of the lease. Repairs and maintenance costs are charged to expense as incurred.
	Impairment of Long-Lived Assets
	The Company periodically evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in Accounting Standards Codification (ASC) 360, Property, Plant & Equipment. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of these assets in relation to the operating performance of the business and the undiscounted cash flows expected to result from the use of these assets. Impairment losses are recognized when the sum of the expected future cash flows is less than the assets' carrying value.
	Goodwill and Acquired Intangible Assets
	Goodwill is the excess of purchase price of an acquired business over the amounts assigned to assets acquired and liabilities assumed in a business combination. In accordance with ASC 350, Intangibles—Goodwill and Other, goodwill is reviewed for impairment annually, or when events arise that could indicate that impairment exists. The provisions of ASC 350 require that the Company perform a two-step impairment test. In the first step, the Company compares the fair value of its reporting units to the carrying value of the reporting units. If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units' goodwill. If the carrying value of the reporting units' goodwill exceeds its implied fair value, an impairment loss equal to the difference is recorded.
	For the purpose of performing its goodwill impairment analysis in 2013, the Company considers its business to be comprised of three reporting units, patient services, product and research services. The Company calculates the fair value of the reporting units utilizing the income and market approaches. The income approach is based on a discounted cash flow methodology that includes assumptions for, among other things, forecasted income, cash flow, growth rates, income tax rates, expected tax benefits and long-term discount rates, all of which require significant judgment. The market approach utilizes the Company's market data. There are inherent uncertainties related to these factors and the judgment applied in the analysis. The Company believes that the combination of an income and a market approach provides a reasonable basis to estimate the fair value of its reporting units.
	Revenue Recognition
	The Company recognizes approximately 78% of its total revenue from patient monitoring services in its patient services segment, derived from its MCOT™, wEvent, event, Holter, Pacemaker and INR services. The Company receives a significant portion of its revenue from third party commercial payors and governmental entities. It also receives reimbursement directly from patients through co-pay, deductibles and self-pay arrangements.
	Revenue from the Medicare program is based on reimbursement rates set by CMS. Revenue from contracted commercial payors is recorded at the negotiated contractual rate. Revenue from non-contracted commercial payors is recorded at net realizable value based on historical payment patterns. Adjustments to the estimated net realizable value, based on final settlement with the third party payors, are recorded upon settlement. If the Company does not have consistent historical information regarding collectability from a given payor, revenue is recognized when cash is received. Unearned amounts are appropriately deferred until service is performed. For the years ended December 31, 2013, 2012 and 2011, revenue from Medicare as a percentage of total Company revenue was 35%, 37% and 33%, respectively.
	Revenue received from the sale of products, product repair and supplies is recognized when shipped, or as service is completed. Unearned amounts are appropriately deferred until service is performed.
	Research services revenue includes revenue for research and core laboratory services. The Company's research services revenues are provided on a fee for service basis, and revenue is recognized as the related services are performed. We also provide consulting services on a time and materials basis and recognize revenues as we perform the services. Our site support revenue, consisting of equipment rentals and sales along with related supplies and logistics management, are recognized at the time of sale or over the rental period. Under a typical contract, customers pay us a portion of our fee for these services upon contract execution as an upfront deposit, some of which is typically nonrefundable upon contract termination. Unearned revenues are deferred, and then recognized as the services are performed.
	For arrangements with multiple deliverables, the revenue is allocated to each element (both delivered and undelivered items) based on their relative selling prices or management's best estimate of their selling prices, when vendor-specific or third-party evidence is unavailable.
	We record reimbursements received for out-of-pocket expenses, including freight, incurred as revenue in the accompanying consolidated statements of operations. Revenue generally is recognized net of any taxes collected from customers and subsequently remitted to government authorities.
	Advertising Costs
	Advertising costs are charged to expense as incurred. For the years ended December 31, 2013, 2012 and 2011, the Company incurred advertising costs of $223, $174 and $218, respectively.
	Research and Development Costs
	Research and development costs are charged to expense as incurred.
	Net Loss
	The Company computes net loss per share in accordance with ASC 260, Earnings Per Share. Basic net loss per share is computed by dividing net loss per share available to common shareholders by the weighted average number of common shares outstanding for the period, and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the treasury stock or if converted methods, as applicable.
	The following summarizes the potential outstanding common stock of the Company as of the end of each period:
		December 31,			December 31,			December 31,
		2013			2012			2011
	Employee stock purchase plan estimated share options outstanding		81,848			50,903			51,544
	Common stock options and restricted stock units ("RSUs") outstanding		3,993,590			3,669,103			2,468,991
	Common stock options available for grant		2,404,498			1,853,786			2,369,802
	Common stock		25,812,754			25,189,340			24,534,601
	Total		32,292,690			30,763,132			29,424,938
	Basic net loss per share is computed by dividing net loss by the weighted average number of fully vested common shares outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common shares, including stock options, and RSUs.
	The following table presents the calculation of historical basic and diluted net loss per share:
		Year Ended December 31,
		2013			2012			2011
		(in thousands, except per share amounts)
	Numerator:
	Net loss	$	(7,319	)	$	(12,202	)	$	(61,422	)
	Denominator:
	Weighted average shares used in computing basic and diluted net loss per share		25,543,646			24,933,656			24,425,318
	Basic and diluted net loss per share	$	(0.29	)	$	(0.49	)	$	(2.51	)
	Stock-Based Compensation
	ASC 718, Compensation—Stock Compensation, addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments of the enterprise or (b) liabilities that are based on the fair value of the enterprise's equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires that an entity measures the cost of equity-based service awards based on the grant-date fair value of the award and recognizes the cost of such awards over the period during which the employee is required to provide service in exchange for the award (the vesting period). ASC 718 requires that an entity measures the cost of liability-based service awards based on current fair value that is re-measured subsequently at each reporting date through the settlement date. The Company accounts for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees.
	Income Taxes
	The Company accounts for income taxes under the liability method, as described in ASC 740, Income Taxes. Deferred income taxes are recognized for the tax consequences of temporary differences between the tax and financial statement reporting bases of assets and liabilities. A valuation allowance for net deferred tax assets is provided unless realizability is judged by the Company to be more likely than not.
	Segment Information
	ASC 280, Segment Reporting, establishes standards for reporting information regarding operating segments in annual financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker, or decision-making group in making decisions on how to allocate resources and assess performance.
	Effective in the third quarter 2012, with the acquisition of Cardiocore, the Company changed its reportable segments from two segments: patient services and product, to three segments: patient services, product and research services. The patient services business segment's principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient TelemetryTM (MCOTTM), wEvent, event, Holter and Pacemaker services, as well as INR services in a healthcare setting. The Product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Research services segment includes the Company's operations that engage in central core laboratory services in a research environment, which includes certain equipment rental and product sales. In addition, the Company realigned the Product segment to exclude central core laboratory research operations previously reported in this segment and repositioned these operations into the Research services segment. Disclosures for the twelve months ended December 31, 2012 have been adjusted to reflect the change in reportable segments.
Recent Accounting Pronouncements
In July 2012, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2012-02, Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment. The new guidance allows an entity the option to first assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that the indefinite-lived intangible asset is impaired. If the qualitative assessment leads to the determination that is more likely than not that the indefinite-lived intangible asset is impaired, then the entity is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount. The ASU is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The amendment did not have a material impact on the Company's results of operations, cash flows, or financial position.
In February 2013, FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. The new guidance requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. The ASU is effective prospectively for reporting periods beginning after December 15, 2012. The amendment did not have a material impact on the Company's results of operations, cash flows, or financial position.
In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The new guidance provides specific financial statement presentation requirements of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance states that an unrecognized tax benefit in those circumstances should be presented as a reduction to the deferred tax asset. The ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company does not expect the amendment to have a material impact on its results of operations, cash flows, or financial position.

Business_Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2013
Business Combinations	'
Business Combinations	'
	3. Business Combinations
	On February 10, 2012, the Company entered into and closed on a definitive Stock Purchase Agreement (the "Stock Purchase Agreement") with ECG Scanning and Medical Services, Inc., an Ohio corporation ("ECG Scanning"). Upon the closing of the transaction, the Company acquired all of the issued and outstanding capital stock, and ECG Scanning became a wholly-owned subsidiary of the Company. ECG Scanning was a provider of cardiac monitoring services in the United States. The Company paid an aggregate cash purchase price of $5,800 at closing and up to an additional $600 in cash, with an estimated fair value of $570, upon the achievement of certain performance targets approximately one year from the date of purchase. At December 31, 2012 the estimated fair value of the earn out was $0. The reduction of the liability was recognized in the Statement of Operations and Comprehensive Income (Loss) in the Integration, restructuring, and other line. The acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition. The acquisition gave the Company access to established customer relationships, and entry into additional regions and geographic locations.
	The purchase price allocation of the ECG Scanning acquisition purchase consideration of $6,370 was completed in the second quarter of 2012. The following table summarizes the purchase price allocation:
	Fair value of assets acquired:
	Cash and cash equivalents	$	32
	Accounts receivable		1,686
	Prepaid expenses and other current assets		141
	Property and equipment		2,655
	Goodwill		1,577
	Intangible assets		1,540
	Other assets		64
	Total assets acquired		7,695
	Liabilities assumed:
	Accounts payable		508
	Accrued expenses		283
	Other liabilities		534
	Total liabilities assumed		1,325
	Net assets acquired	$	6,370
	On August 29, 2012, the Company entered into a definitive merger agreement with Cardicore Lab, Inc. ("Cardiocore"), a Delaware corporation. Upon the closing of the transaction, Cardiocore became a wholly-owned subsidiary of the Company. The Company paid an aggregate purchase price of $23,500 in cash at closing. The acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition.
	Cardiocore is engaged in central core laboratory services that provide cardiac monitoring for drug and medical treatment trials. Cardiocore's primary customers are pharmaceutical companies and contract research organizations. The acquisition gave the Company access to industry expertise, an established operating structure and a substantial footprint in the core laboratory industry.
	The purchase price allocation of the Cardiocore acquisition purchase consideration of $23,500 was completed in the fourth quarter of 2012. The following table summarizes the purchase price allocation:
	Fair value of assets acquired:
	Cash and cash equivalents	$	1,113
	Accounts receivable		4,290
	Prepaid expenses and other current assets		386
	Property and equipment		4,230
	Goodwill		11,506
	Intangible assets		6,920
	Total assets acquired		28,445
	Liabilities assumed:
	Accounts payable		1,195
	Accrued expenses		1,215
	Deferred tax liabilities		935
	Deferred revenue		1,600
	Total liabilities assumed		4,945
	Net assets acquired	$	23,500
	The unaudited pro forma information below presents combined results of operations as if the acquisition had occurred at the beginning of the periods presented instead of August 29, 2012. The pro forma information is based on historical results adjusted for the effect of purchase accounting and is not necessarily indicative of the results of operations of the combined entity had the acquisition occurred at the beginning of the periods presented, nor is it necessarily indicative of future results.
		December 31,
		2012			2011
	Revenue	$	124,698		$	134,102
	Net Income (Loss)	$	(10,936	)	$	(62,712	)
	Net Income per common share:
	Basic and Diluted	$	(0.47	)	$	(2.56	)
	Weighted average number of shares:
	Basic		24,933,656			24,425,318

Inventory

Inventory	12 Months Ended
	Dec. 31, 2013
Inventory	'
Inventory	'
	4. Inventory
	Inventory consists of the following:
		December 31,
		2013		2012
	Raw materials and supplies	$	2,404	$	2,782
	Finished goods		150		112
	Total inventories	$	2,554	$	2,894
	Inventories, which include purchased parts, materials, direct labor and applied manufacturing overhead, are stated at the lower of cost or net realizable value, with cost determined by use of the first-in, first-out method.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property and Equipment	'
Property and Equipment	'
	5. Property and Equipment
	Property and equipment consists of the following:
			December 31,
		Estimated
		Useful Life
		(Years)	2013			2012
	Cardiac monitoring devices, device parts and components	3 - 5	$	37,273		$	52,943
	Computers and purchased software	3 - 5		13,302			12,088
	Equipment, tools and molds	3		5,384			6,591
	Furniture and fixtures	3		2,863			3,476
	Leasehold improvements	Life of lease		2,665			5,828
	Capital leases	5		737			—
	Total property and equipment, at cost			62,224			80,926
	Less accumulated depreciation			(43,445	)		(61,075	)
	Total property and equipment, net		$	18,779		$	19,851
	Depreciation expense associated with property and equipment was $9,978, $8,037 and $10,913, for the years ended December 31, 2013, 2012 and 2011, respectively.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets	'
Goodwill and Intangible Assets	'
	6. Goodwill and Intangible Assets
	Goodwill was recognized at the time of the Cardiocore, ECG, Biotel and PDSHeart acquisitions. The carrying amount of goodwill as of December 31, 2013 and 2012 was $16,469 and $16,446, respectively.
	The changes in the carrying amounts of goodwill by segment were as follows:
		Reporting Segment
		Patient			Research			Product		Total
		Services			Services
	Balance at December 31, 2012	$	1,577		$	11,712		$	3,157	$	16,446
	Goodwill acquired during the year		—			23			—		23
	Balance at December 31, 2013	$	1,577		$	11,735		$	3,157	$	16,469
	The gross carrying amounts and accumulated amortization of the Company's intangible assets as of December 31, 2013 and 2012 are as follows:
				December 31,
		Estimated
		Useful Life
		(Years)		2013			2012
	Customer relationships	6 - 10		$	2,100		$	3,651
	Proprietary technology	5			4,000			4,000
	Signed backlog	1 - 4			2,800			2,800
	Unsigned backlog	4			600			600
	Covenants not to compete	5			360			360
	Total intangible assets, gross				9,860			11,411
	Customer relationships accumulated amortization				(722	)		(1,894	)
	Proprietary technology accumulated amortization				(1,902	)		(676	)
	Signed backlog accumulated amortization				(1,400	)		(875	)
	Unsigned backlog accumulated amortization				(200	)		(50	)
	Covenants not to compete accumulated amortization				(124	)		(52	)
	Total accumulated amortization				(4,348	)		(3,547	)
	Indefinite-lived trade name				1,800			1,800
	Total intangible assets, net			$	7,312		$	9,664
	The estimated amortization expense for the next five years is summarized as follows at December 31, 2013:
	2014	$	2.294
	2015		1,938
	2016		842
	2017		138
	2018		100
	Total	$	5,312
	Amortization expense for the years ended December 31, 2013, 2012 and 2011 was $2,340, $1,341 and $1,219, respectively.
	At December 31, 2013 and 2012, the Company performed its required annual impairment test of goodwill. Based on this impairment test, the Company determined that none of the reporting unit's goodwill was impaired.
	At December 31, 2011, the Company performed its required annual impairment test of goodwill. Based on this impairment test, the Company determined that its Product reporting unit's goodwill was not impaired. However, as a result of the impairment test, the Company determined that impairment may exist in the patient services reporting unit. Therefore, the Company performed Step 2 of the goodwill impairment analysis on its patient services reporting unit.
	The Step 2 analysis was performed by allocating the fair value of the patient services reporting unit to the identifiable assets, including unrecorded intangible assets and liabilities. This allocation is performed as if the reporting unit had been acquired in a business combination, and assumes the purchase price was equivalent to the fair value determined in Step 1 of the goodwill impairment test. The residual fair value of the reporting unit after allocation is the implied fair value of goodwill. This value is then compared to the carrying value of the reporting unit's goodwill. If the implied fair value of goodwill is less than the carrying value, impairment exists and a charge is recorded in the amount of the difference. As a result of the Company's analysis, an impairment charge of $45,999 was recorded for the year ended December 31, 2011 related to the patient services reporting unit.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Accrued Expenses	'
Accrued Expenses	'
	7. Accrued Expenses
	Accrued expenses consisted of the following:
		December 31,
		2013		2012
	Accrued compensation	$	4,932	$	6,382
	Accrued professional fees		1,922		544
	Accrued purchases		311		197
	Accrued restructuring costs		96		914
	Other		929		1,909
	Total	$	8,190	$	9,946

Integration_Restructuring_and_

Integration, Restructuring and Other Charges	12 Months Ended
	Dec. 31, 2013
Integration, Restructuring and Other Charges	'
Integration, Restructuring and Other Charges	'
	8. Integration, Restructuring and Other Charges
	2013 Integration, Restructuring and Other Charges
	For the year ended December 31, 2013, the Company incurred expenses related to restructuring, integration and other activities. A summary of these expenses is as follows:
	Legal fees	$	5,516
	Severance and employee related costs		1,410
	Expenses related to facility closure		564
	Professional fees		492
	Total	$	7,982
	The Company accounts for expenses associated with exit or disposal activities in accordance with ASC 420, Exit or Disposal Cost Obligations, and records the expenses in "Integration, restructuring and other charges" in its statement of operations, and records the related accrual in the "Accrued expenses" line of its balance sheet.
	In 2013, the Company incurred other charges of $5,516 relating primarily to legal fees for patent litigation. In addition, the Company incurred $1,410 of severance and employee related costs due to restructuring and integration related activities, $564 of asset impairment charges related to the closure of a small monitoring center located in Michigan and $492 of professional fees related to corporate restructuring activities.
	2012 Integration, Restructuring and Other Charges
	For the year ended December 31, 2012, the Company incurred expenses related to restructuring, integration and other activities. A summary of these expenses is as follows:
	Legal fees	$	1,780
	Severance and employee related costs		1,490
	Professional fees		778
	Other charges		188
	Total	$	4,236
	The Company accounts for expenses associated with exit or disposal activities in accordance with ASC 420, Exit or Disposal Cost Obligations, and records the expenses in "Integration, restructuring and other charges" in its statement of operations, and records the related accrual in the "Accrued expenses" line of its balance sheet.
	In 2012, integration, restructuring and other charges included legal fees of $1,780 related to litigation and transaction due diligence, $778 related to professional services associated with transaction due diligence, $1,490 related to severance and other employee related costs and $188 related to other restructuring charges.
	2011 Integration, Restructuring and Other Charges
	For the year ended December 31, 2011, the Company incurred expenses related to restructuring, integration and other activities. A summary of these expenses is as follows:
	Legal fees	$	2,835
	Biotel integration		1,023
	Professional fees		639
	Other charges		162
	Total	$	4,659
	In 2011, integration, restructuring and other charges included legal fees of $2,835 related to litigation, $639 related to professional services associated with transaction due diligence and $162 related to severance and other employee related costs.
	Restructuring and integration costs of $1,023 were related to severances and other employee related costs associated with the acquisition of Biotel. The restructuring activities related to Biotel were substantially complete as of December 31, 2011.

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2013
Shareholders' Equity	'
Shareholders' Equity	'
	9. Shareholders' Equity
	Common Stock
	As of December 31, 2013 and 2012, the Company was authorized to issue 200,000,000 shares of common stock. As of December 31, 2013 and 2012, the Company had 25,812,754 and 25,189,340 shares outstanding, respectively.
	Preferred Stock
	The Company maintains an unregistered blank check preferred stock class. As of December 31, 2013 and 2012, there are no shares authorized and outstanding.
	Stock Based Compensation
	2008 Equity Incentive Plan
	The Company's 2008 Equity Incentive Plan (the 2008 Option Plan) became effective on March 18, 2008. The Plan permits the Company's Board of Directors to grant incentive stock options to employees of the Company and non-qualified stock options, restricted stock, performance stock and other stock-based incentive awards to officers, directors, employees and consultants of the Company. On that date, the Company began granting options to purchase shares of common stock to employees, executives, directors and consultants. Under the terms of the 2008 Option Plan, all available shares in the 2003 Option Plan's share reserve automatically roll into the 2008 Option Plan. Any cancellations or forfeitures of granted options under the 2003 Option Plan also automatically roll into the 2008 Option Plan. Beginning on January 1, 2009, and each year thereafter, the number of options available to be granted under the plan will increase by the lesser of 4% of the total number of common shares outstanding or 1,500,000 shares.
	Options granted under the 2008 Option Plan have exercise prices not less than the fair market value at the date of grant and have an expiration date of no greater than ten years from the date of grant. There is no vesting schedule provided in the 2008 Option Plan, and vesting is determined by the Board of Directors on the date of grant.
	2008 Non-employee Directors' Stock Option Plan
	As of October 23, 2008, the Company no longer granted options to purchase shares of common stock to non-employee directors under the Company's 2008 Non-employee Directors' Stock Option Plan (the 2008 Directors' Plan). The Company's 2008 Directors' Plan became effective March 18, 2008. Beginning on that date, all directors elected for the first time to the Board of Directors receive a fixed number of options. On the date of the annual meeting, and when directors are elected to a committee or a chair position of a committee, they will also receive a grant equal to a fixed number of options per the Directors' Plan. Options granted under the Directors' Plan have exercise prices not less than the fair market value at the date of grant, and have an expiration date of no greater than ten years from the date of grant. Initial and committee chair grants vest 33% on the first anniversary date of grant, and the balance vests ratably over 24 months. Annual grants vest ratably over 12 months from the date of grant.
	2003 Equity Incentive Plan
	As of March 18, 2008, the Company no longer granted options to purchase shares of common stock to employees, executives, directors and consultants under the Company's 2003 Equity Incentive Plan (the 2003 Option Plan). Options granted under the 2003 Option Plan have exercise prices not less than the fair market value at date of grant for incentive stock options and not less than 85% of the fair market value at the date of grant for non-statutory options. The options generally expire ten years from the date of grant and generally vest 25% twelve months from the date of grant, and ratably over the next 36 months thereafter.
	The 2003 Option Plan allows for employees to early exercise options on the first anniversary date of employment, regardless of the vested status of granted options. If an employee terminates prior to fully vesting in options that have been early exercised, the Company repurchases the common stock associated with unvested options at the original exercise price.
	Option and RSU activity under all equity incentive plans is summarized as follows for the years ended December 31, 2013, 2012 and 2011:
					Options/RSU's Outstanding
		Shares			Number			Weighted
		Available			of Shares			Average
		for Grant						Exercise Price
	Balance—December 31, 2010		1,649,723			2,102,376		$	12.18
	Additional shares authorized for grant		1,207,210			—			—
	Granted		(724,333	)		724,333		$	4.67
	Cancelled/forfeited		237,202			(237,202	)	$	15.1
	Exercised/vesting		—			(120,516	)	$	7.78
	Balance—December 31, 2011		2,369,802			2,468,991		$	9.43
	Additional shares authorized for grant		1,216,611			—			—
	Granted		(2,128,939	)		2,128,939		$	2.73
	Cancelled/forfeited		396,312			(396,312	)	$	9.98
	Exercised/vesting		—			(532,515	)	$	7.85
	Balance—December 31, 2012		1,853,786			3,669,103		$	5.83
	Additional shares authorized for grant		1,260,768			—			—
	Granted		(1,186,639	)		1,186,639		$	3.35
	Cancelled/forfeited		476,583			(476,583	)	$	5.41
	Exercised/vesting		—			(385,569	)	$	4.6
	Balance—December 31, 2013		2,404,498			3,993,590		$	5.25
	A summary of total outstanding stock options as of December 31, 2013 is as follows:
		Options Outstanding									Options Exercisable
	Range of Exercise	Number			Weighted-			Weighted-			Number		Weighted-		Weighted-
	Price	Outstanding			Average			Average			Exercisable		Average		Average
					Remaining			Exercise Price					Remaining		Exercise Price
					Contractual								Contractual
					Life (in years)								Life (in years)
	$0.70 - $7.50		2,715,216			7.81		$	3.82			1,279,892		7.24	$	4.52
	$7.51 - $15.00		90,796			8.17		$	9.5			34,546		5.59	$	9.23
	$15.01 - $22.50		249,522			5.28		$	18.4			249,522		5.28	$	18.4
	$22.51 - $31.18		80,400			4.62		$	30.17			80,400		4.62	$	30.17
	$0.70 - $31.18		3,135,934			7.54		$	5.82			1,644,360		6.78	$	7.98
	In addition, a summary of total outstanding RSU's as of December 31, 2013 is as follows:
	Range of Grant Price	RSU's
		Outstanding
	$2.16 - $6.75		844,943
	$6.76 - $9.75		12,713
	$2.16 - $9.75		857,656
	The table below summarizes certain additional information with respect to our options:
	(In thousands)	2013			2012			2011
	Aggregate intrinsic value of options outstanding at year-end	$	11,183		$	46		$	17
	Aggregate intrinsic value of options exercisable at year-end		4,382			13			17
	Aggregate intrinsic value of options exercised during the year		422			2			7
	As of December 31, 2013, 2012 and 2011, the Company has reserved shares of common stock for issuance as follows:
		December 31,
		2013			2012			2011
	Exercise of options available and grants of awards under equity plans		6,398,088			5,522,889			4,838,793
	The Company's loss before income taxes for the years ended December 31, 2013, 2012 and 2011 was $3,303, $3,747 and $4,006 lower, respectively, as a result of stock- based compensation expense incurred. For the year ended December 31, 2013, the impact of stock-based compensation expense was $(0.13) on the basic and diluted earnings per share. The impact of stock-based compensation expense was $(0.15) and $(0.16) on the basic and diluted earnings per share for the years ended December 31, 2012 and 2011. Stock-based compensation expense was recorded in general and administrative expenses for the years ended 2013, 2012 and 2011.
Total cash received from the exercise of stock options for the year ended December 31, 2013, 2012 and 2011 was $467, $4 and $11, respectively. The tax benefit was fully reserved for through a tax valuation allowance.
The Company estimates the fair value of its share-based awards to employees and directors using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the use of certain subjective assumptions. The most significant of these assumptions are the estimates of the expected volatility of the market price of the Company's stock and the expected term of the award. We base our estimates of expected volatility on the historical volatility of our stock price. The expected term represents the period of time that stock-based awards granted are expected to be outstanding. Other assumptions used in the Black-Scholes option valuation model include the risk-free interest rate and expected dividend yield. The risk-free interest rate for periods pertaining to the contractual life of each option is based on the U.S. Treasury yield of a similar duration in effect at the time of grant. The Company has never paid, and does not expect to pay, dividends in the foreseeable future.
The fair value of the Company's stock-based awards was estimated at the date of grant using the following weighted average assumptions:
	Year Ended
	December 31,
	2013			2012			2011
Expected volatility		60.3	%		63.4	%		62	%
Expected term (in years)		6.71			6.31			6.25
Weighted-average risk-free interest rate		1.34	%		1.15	%		2.48	%
Expected dividends		0	%		0	%		0	%
Weighted-average grant date fair value per share	$	1.9		$	1.58		$	2.82
Based on the Company's historical experience of options that cancel before becoming fully vested, the Company has assumed an annualized forfeiture rate of 15% for all options. Under the true-up provision of ASC 718, the Company will record additional expense if the actual forfeiture rate is lower than estimated, and will record a recovery of prior expense if the actual forfeiture rate is higher than estimated.
Total compensation cost of options granted but not yet vested at December 31, 2013, 2012 and 2011 were approximately $2,644, $3,433 and $3,615, respectively. At December 31, 2013, 2012 and 2011, the weighted average remaining periods over which the above amounts are expected to be recognized were 2.14 years, 2.34 years and 2.62 years, respectively. At December 31, 2013, 2,404,498 shares remained available for future grant under the Plan.
A summary of the status of the Company's unvested stock options and RSU's as of the respective balance sheet dates, and changes during years, is presented below:
	Number of			Weighted-
	Shares			Average
				Grant-Date
				Fair Value
				(per share)
Unvested shares at December 31, 2012		2,436,702		$	2.62
Granted		1,186,639		$	2.52
Vested		(797,528	)	$	3.14
Cancelled/forfeited		(476,583	)	$	3.49
Unvested shares at December 31, 2013		2,349,230		$	2.45
Option Acceleration
On December 1, 2009, the Company accelerated the vesting of certain employees' unvested options that were deeply out-of-the-money. The acceleration was done because the Company believed that there was no longer a compensation incentive tied to Company performance, given the exercise price of the options that were accelerated. Consistent with ASC 718, the Company will continue to expense the accelerated options over the remaining service period. The Company does not have a static policy threshold to use for determining whether an option is deeply out-of-the-money. Rather, the Company believes that the determination should be made in light of current market conditions, probability of stock price recovery within the remaining service period, and historical volatility of the Company's stock price. For the purposes of this option acceleration, the Company determined that options that were out-of-the-money by 30% or more were deeply out-of-the-money. As a result of the option acceleration, approximately 309,000 previously unvested shares became fully vested on December 1, 2009. The Company incurred an expense associated with the options that were accelerated in the amount of $137, $578 and $984 for the years ended December 31, 2013, 2012 and 2011, respectively, which have been recorded in the General and administrative line of the consolidated statement of operations and comprehensive income (loss). The weighted average exercise price of the accelerated options is $19.87, and the remaining service period has elapsed.
Employee Stock Purchase Plan
In July 2008, the Company made available an employee stock purchase plan in which substantially all of the Company's full-time employees became eligible to participate effective March 18, 2008. Under the plan, employees may contribute through payroll deductions up to 15% of their compensation toward the purchase of the Company's common stock, or $21, whichever is lower. The price per share is equal to the lower of 85% of the fair market price on the first day of the offering period, or 85% of the fair market price on the day of purchase. Proceeds received from the issuance of shares are credited to stockholders' equity in the period that the shares are issued. In 2013, 243,185 shares were purchased in accordance with the Employee Stock Purchase Plan (ESPP). Net proceeds to the Company from the issuance of shares of common stock under the ESPP for the year ended December 31, 2013 were $487. In January 2013, the number of shares available for grant was increased by 252,154, per the ESPP plan documents. At December 31, 2013, approximately 517,456 shares remain available for purchase under the ESPP. For the years ended December 31, 2013, 2012 and 2011, the Company incurred ESPP expenses of $211, $182 and $201, respectively.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Income Taxes	'
	10. Income Taxes
	The Company has deferred income tax assets totaling $53,584 at December 31, 2013, consisting primarily of federal and state net operating loss and credit carryforwards. Due to uncertainty regarding the ultimate realization of these net operating loss and credit carryforwards and other deferred income tax assets, we have established a full valuation allowance on our deferred tax assets and will recognize the benefits only as reassessment indicates the benefits are realizable. The determination of the required valuation allowance against net deferred tax assets was made without taking into account the deferred tax liabilities created from the book and tax differences on indefinite-lived assets.
	The Company's income tax expense for 2013 of $215 primarily relates to state taxes based on gross receipts or modified gross receipts calculations properly included as income taxes.
	The Company performed an analysis to determine the extent to which it can use its net operating loss carryforwards in future periods, subject to certain limitations imposed by the Internal Revenue Code. The Company concluded that because of the Company's limited history of reporting a net profit, it cannot predict that the benefits of the net operating loss carryfowards will be realized in future periods, and therefore the Company continues to provide a full valuation allowance for deferred tax assets. The Company will perform a similar analysis during 2014 to reassess the estimated future realizability of net operating loss carryforwards.
	Deferred taxes result from temporary differences between the carrying amounts of assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes. The significant components of the Company's deferred tax assets and liabilities are as follows:
		December 31,
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards	$	37,335		$	37,384
	Research & development and AMT credit carryforwards		4,687			4,530
	Stock option grants		6,533			5,329
	Allowance for doubtful accounts		3,101			2,932
	Other, net		1,928			2,210
	Total deferred tax assets		53,584			52,385
	Less valuation allowance		(50,979	)		(49,145	)
	Net deferred tax assets	$	2,605		$	3,240
	Deferred tax liabilities:
	Property, plant and equipment		(345	)		(815	)
	Identified intangible assets		(2,089	)		(2,404	)
	Indefinite lived intangible assets		(730	)		(678	)
	Prepaid insurance		(171	)		(21	)
	Total deferred tax liabilities		(3,335	)		(3,918	)
	Net deferred tax liability		(730	)		(678	)
	Reconciliations between expected income taxes computed at the federal rate of 35% for each of the years ended December 31, 2013, 2012 and 2011, and the provision (benefit) for income taxes is as follows:
		Years ended December 31,
		2013			2012			2011
	Income tax benefit at statutory rate	$	(2,486	)	$	(4,587	)	$	(21,412	)
	State income tax, net of federal benefit		716			(211	)		191
	Stock-based compensation		203			397			493
	Nondeductible goodwill impairment		—			—			16,100
	Other		182			200			(173	)
	Increase in valuation allowance		1,600			3,296			5,045
	Income tax provision (benefit)	$	215		$	(905	)	$	244
	At December 31, 2013, the Company had federal net operating loss carryforwards of approximately $96,588, to offset future federal taxable income expiring in various years through 2030. At December 31, 2013, the Company had state net operating loss carryforwards of $54,243, which expire in various years starting in 2014.
	The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. The timing and manner in which the Company can utilize its net operating loss carryforward and future income tax deductions in any year may be limited by provisions of the Internal Revenue Code regarding the change in ownership of corporations. Such limitation may have an impact on the ultimate realization of the Company's carryforwards and future tax deductions. Section 382 of the Internal Revenue Code ("Section 382") imposes limitations on a corporation's ability to utilize net operating losses if it experiences an "ownership change." In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50 percentage points over a three-year period. Any unused annual limitation may be carried over to later years, and the amount of the limitation may under certain circumstances be increased by the built-in gains in assets held by the Company at the time of the change that are recognized in the five-year period after the change. Currently, the Company's loss carryforwards are limited under Section 382.
	The components of the Company's income tax (benefit) provision are summarized as follows:
		Year Ended
		December 31,
		2013			2012
	Current:
	Federal	$	24		$	—
	State		138			128
	Total current provision for income taxes		162			128
	Deferred:
	Federal		—			(996	)
	State		53			(37	)
	Total deferred provision (benefit) for income taxes		53			(1,033	)
	Total provision (benefit) for income taxes	$	215		$	(905	)
	The U.S. Internal Revenue Service concluded its examination of the Company's U.S. federal tax returns for all years through 2010. Because of net operating losses, the Company's U.S. federal tax returns for those years will remain subject to examination until the losses are utilized.
	The Company does not have a tax reserve recorded for tax contingencies. As of December 31, 2013 and 2012, the Company has not identified any uncertain tax positions and therefore, it has no tax reserve recorded as of December 31, 2013 and 2012.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies	'
Commitments and Contingencies	'
	11. Commitments and Contingencies
	Leases
	The Company leases its principal administrative and service facilities as well as office equipment under non-cancelable operating leases expiring at various dates through 2021. The terms of the leases are renewable at the end of the lease term. Payments made under operating leases are charged to operations on a straight-line basis over the period of the lease. Differences between straight-line expense and cash payments are recognized in the deferred rent line of the balance sheet. Rent expense was $3,622, $2,946 and $2,713 for the years ended December 31, 2013, 2012 and 2011, respectively.
	During 2013, the Company entered into a capital lease expiring June 2017 to finance equipment relating to technology.
	Future minimum lease payments under non-cancelable operating and capital leases are summarized as follows at December 31, 2013:
		Operating		Capital
		Leases		Leases
	2014	$	2,250	$	205
	2015		2,195		205
	2016		1,881		205
	2017		1,749		103
	2018		1,732		—
	Thereafter		2,227		—
		$	12,034	$	718
	Other
	The Company has an agreement with Verizon whereby the Company has no fixed or minimum financial commitment. However, in the event the Company fails to maintain an agreed upon number of active cardiac monitoring devices on the Verizon network, Verizon has the right to terminate this agreement.

Credit_Agreement

Credit Agreement	12 Months Ended
	Dec. 31, 2013
Credit Agreement	'
Credit Agreement	'
	12. Credit Agreement
	On August 29, 2012, the Company entered into a Credit and Security Agreement ("Credit Agreement") with MidCap Financial, LLC to provide revolving loan borrowings with a loan commitment of up to $15,000, and an option by the Company to increase to a maximum loan commitment of $30,000. Interest on borrowings under the Credit Agreement is based on the London Interbank Offered Rate ("LIBOR") plus a margin of 4.75%. An unused line fee of 0.50% per annum is payable on any unused line balance, determined as the total loan commitment of $15,000 minus the average daily balance of the sum of the revolving loan borrowings outstanding during the preceding month. Furthermore, if the Company terminates the agreement at any point prior to the loan expiration date, the Company will incur a loan termination fee of 1.00% of the loan commitment due immediately preceding the termination. The Credit Agreement is secured by the Company's personal property, inventory and other assets and expires in August 2016. As of December 31, 2013, the Company did not have any outstanding balance on the credit agreement.

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2013
Employee Benefit Plan	'
Employee Benefit Plan	'
	13. Employee Benefit Plan
	The Company sponsors a 401(k) Retirement Savings Plan (the Plan) for all eligible employees who meet certain requirements. Participants may contribute, on a pre-tax basis, up to the maximum allowable amount pursuant to Section 401(k) of the Internal Revenue Code. The Company is not required to contribute to the Plan. In May 2009, the Company adopted an amendment to the Plan that allowed for an employer matching contribution of 100% of employee contributions, up to 3% of the employees' salary. In January 2012, the Company adopted an amendment to eliminate the employers' matching contribution. For the years ended December 31, 2013, 2012 and 2011, the Company contributed $0, $0 and $1,296, respectively. Employer contributions vest immediately.

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2013
Segment Information	'
Segment Information	'
	14. Segment Information
	The Company operates under three segments: patient services, product, and research services. Prior to 2012, the company operated under two segments: patient services and product. The patient services business segment's principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry™ ("MCOT™"), wEvent, event, Holter and Pacemaker services, as well as INR services in a healthcare setting . The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company's research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. Intercompany revenue relating to the manufacturing of devices by the product segment for the other segments is included on the intersegment revenue line.
	Expenses that can be specifically identified with a segment have been included as deductions in determining pre-tax segment income. Any remaining expenses including research and development costs incurred by the product segment for the benefit of the other segments as well as the elimination of costs associated with intercompany revenue are included in Corporate and Other. Also included in Corporate and Other are net financing expenses and other, which consist principally of interest expense and debt and other financing expenses less interest income. The Company does not allocate assets to the individual segments.
		Patient		Research		Product		Corporate			Consolidated
		Services		Services				and Other
	2013
	Revenues	$	100,386	$	20,329	$	8,786	$	—		$	129,501
	Intersegment revenues		—		—		6,191		(6,191	)		—
	Income (loss) before income taxes		27,298		798		5,307		(40,507	)		(7,104	)
	Depreciation and amortization		4,253		4,057		551		3,457			12,318
	Capital expenditures		5,796		2,242		131		—			8,169
		Patient		Research		Product		Corporate			Consolidated
		Services		Services				and Other
	2012
	Revenues	$	93,640	$	8,333	$	9,521	$	—		$	111,494
	Intersegment revenues		—		—		2,141		(2,141	)		—
	Income (loss) before income taxes		13,284		1,556		3,770		(31,717	)		(13,107	)
	Depreciation and amortization		5,161		974		428		2,815			9,378
	Capital expenditures		4,199		1,079		684		—			5,962

Legal_Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2013
Legal Proceedings	'
Legal Proceedings	'
	15. Legal Proceedings
	CardioNet v. Mednet Litigation
	On May 8, 2012, CardioNet, Inc. filed suit against Mednet Healthcare Technologies, Inc., MedTel 24, Inc., RhythmWatch LLC, and AMI Cardiac Monitoring, Inc., in the United States District Court for the Eastern District of Pennsylvania (Civil Action No. 2:12-CV-2517-JS) for patent infringement related to the making, use, offering for sale, and sale of the Heartrak ECAT device and monitoring services. The suit asserted that the defendants are infringing CardioNet's U.S. Patent Nos. 7,212,850, 7,907,996, 6,569,095, 7,587,237 and 7,941,207. CardioNet sought an injunction against each defendant, as well as monetary damages. The defendants asserted counterclaims alleging the patents in suit are invalid and not infringed.
	This litigation concluded on January 31, 2014 when the Court entered a Consent Judgment declaring all five CardioNet patents valid and enforceable, and infringed by the defendants' making, using, offering to sell, or selling the Heartrak ECAT device and monitoring services. The Consent Judgment also declared that all defendants are permanently enjoined from further infringement and are required to turn over all existing inventory of the Heartrak ECAT system to CardioNet and Braemar.
	Simultaneously with the entry on of the consent judgment the Company, through its CardioNet subsidiary, entered into a definitive stock purchase agreement, to purchase all of the outstanding capital stock of Mednet and its affiliated entities for consideration of $5.5 million in cash and 96,649 shares of the Company's common stock. In addition, as a result of the acquisition, the Company, through CardioNet, assumed outstanding secured debt of the Mednet entities in the aggregate amount of approximately $10 million, including interest.
	CardioNet v. ScottCare Litigation
	On May 8, 2012, CardioNet, Inc. filed suit against The ScottCare Corporation and Ambucor Health Solutions, Inc. in the United States District Court for the Eastern District of Pennsylvania (Civil Action No. 2:12-CV-2516-PBT) for patent infringement under the same five CardioNet patents, as mentioned above in the Mednet litigation, related to the making, use, sale, and offering for sale of the ScottCare TeleSentry Mobile Cardiac Telemetry device and monitoring services. CardioNet is seeking an injunction against each defendant, as well as monetary damages. The ScottCare Corporation has asserted counterclaims alleging the patents in suit are invalid and not infringed.
	On May 10, 2013, CardioNet, Inc. and Braemar Manufacturing, LLC filed an Amended Complaint identifying Braemar as the new owner of all right, title and interest to the patents-in-suit with CardioNet as the exclusive licensee of these patents. Fact discovery is scheduled to close on April 17, 2014, with trial scheduled for November 10, 2014. Consistent with the accounting for contingent liabilities, no accrual has been recorded in the financial statements. The Company is vigorously pursuing its claims and defending against the counterclaims.
	CardioNet v. LifeWatch Litigation
	On June 12, 2012, CardioNet, Inc. settled the patent infringement action brought on September 25, 2009 by LifeWatch Services, Inc., and Card Guard Scientific Survival, Ltd. ("Lifewatch"), the licensee and owner, respectively, of U.S. Patent Nos. 7,542,878 B2 ("the '878 Patent") and 5,730,143 ("the '143 Patent"), collectively ("Licensed Patents") against the Company's wholly owned subsidiary, Braemar Inc. ("Braemar") and one of its customers, eCardio Diagnostics, LLC ("eCardio"), in Federal District Court for the Northern District of Illinois, File No. 09-CV-6001. In this matter, Lifewatch alleged that Braemar and eCardio had infringed the Licensed Patents. Pursuant to the terms of the settlement agreement, the Company paid Lifewatch a lump sum of $250 for a fully paid license, release, and covenant not to sue under the Licensed Patents for Braemar products. The covenant not to sue extends to Braemar's customers, including eCardio.

Civil_Investigative_Demand

Civil Investigative Demand	12 Months Ended
	Dec. 31, 2013
Civil Investigative Demand	'
Civil Investigative Demand	'
	16. Civil Investigative Demand
	On August 25, 2011, the Company received a Civil Investigative Demand ("CID") issued by the U.S. Department of Justice, Western District of Washington. The CID states that it was issued in the course of an investigation under the federal false claims act and seeks documents for the period January 1, 2007 through the date of the CID. The CID indicates that the investigation concerns allegations that the Company may have used inappropriate diagnosis codes when submitting claims for payment to Medicare for its real-time, outpatient cardiac monitoring services. The Company is cooperating with the government's request and is in the process of providing information in response to the CID. The Company is unable to predict what action, if any, might be taken in the future by the Department of Justice or other governmental authorities as a result of this investigation or what impact, if any, the outcome of this matter might have on the Company's business, financial position or results of operations. The Company cannot reasonably estimate the range of loss, if any, that may result from this matter. Consistent with the accounting for contingent liabilities, no accrual has been recorded in the financial statements.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Data (Unaudited)	'
Quarterly Financial Data (Unaudited)	'
	17. Quarterly Financial Data (Unaudited)
	The following tables summarize the unaudited quarterly financial data for the last two fiscal years.
		First			Second			Third			Fourth
		Quarter			Quarter			Quarter			Quarter
		(in thousands, except per share amount)
	2013
	Total revenues	$	32,418		$	32,104		$	31,874		$	33,105
	Gross profit		19,545			19,496			19,234			20,795
	Integration, restructuring and other charges		1,202			2,541			3,077			1,162
	Income (loss) from operations		(2,034	)		(2,238	)		(2,835	)		226
	Net income (loss)		(2,087	)		(2,299	)		(2,956	)		23
	Basic and diluted net income (loss) per share	$	(0.08	)	$	(0.09	)	$	(0.12	)	$	0
	2012
	Total revenues	$	27,045		$	27,450		$	27,040		$	29,959
	Gross profit		15,610			16,726			16,398			17,167
	Integration, restructuring and other charges		270			733			741			2,492
	Loss from operations		(3,581	)		(1,668	)		(3,126	)		(4,784	)
	Net loss		(3,534	)		(1,198	)		(3,121	)		(4,349	)
	Basic and diluted net loss per share	$	(0.14	)	$	(0.05	)	$	(0.12	)	$	(0.17	)

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events	'
Subsequent Events	'
	18. Subsequent Events
	On January 31, 2014, the Company, through its wholly-owned subsidiary CardioNet, acquired Mednet Healthcare Technologies, Inc., Heartcare Corporation of America, Inc., Universal Medical, Inc., and Universal Medical Laboratory, Inc. (together, the "Mednet entities") from Frank Movizzo ("Seller"), pursuant to the terms and conditions of a Stock Purchase Agreement among CardioNet, the Mednet entities and Mr. Movizzo (the "Purchase Agreement").
	The Purchase Agreement was entered into following the entry of a consent judgment in connection with the Company's patent infringement action originally filed in the U.S. District Court for the Eastern District of Pennsylvania in May 2012 against the Mednet entities and other companies. The consent judgment declared that the Mednet entities infringed five patents owned by the Company and its subsidiary, Braemar Manufacturing, LLC, and that all five patents are valid.
	Pursuant to the terms of the Purchase Agreement, CardioNet purchased all of the outstanding capital stock of the Mednet entities from the Seller for consideration of $5.5 million in cash and 96,649 shares of the Company's common stock. In addition, as a result of the acquisition, the Company, through CardioNet, assumed outstanding secured debt of the Mednet entities in the aggregate amount of approximately $10 million, including interest.
	On February 21, 2014, the Company came to an agreement with the third party lenders to refinance this debt. The Loans bear interest at an annual rate of 3.25% until March 1, 2019, and thereafter will bear interest at an annual rate equal to the greater of (1) 3.25% or (2) the prime rate as published in the "Money Rates" section of The Wall Street Journal (or it successor) or the highest prime rate if more than one is published. Beginning April 1, 2014, the principal amount of the Loans will be repaid, on a monthly basis, in installments of $37,500, plus accrued interest, until April 1, 2019, when the principal amount of the Loans will be repaid, on a monthly basis, in installments of $75,000, plus accrued interest, until paid in full on or before March 1, 2024 (or such earlier date upon an acceleration of the Loans by Lenders upon an event of default or termination by the Borrowers).

Schedule_IIValuation_and_Quali

Schedule II-Valuation and Qualifying Accounts and Reserves	12 Months Ended
	Dec. 31, 2013
Schedule II-Valuation and Qualifying Accounts and Reserves	'
Schedule II-Valuation and Qualifying Accounts and Reserves	'
	SCHEDULE II
		Beginning		Additions		Deductions			Ending
		Balance		Charged To		From			Balance
				Expense		Reserve
	Allowance for Doubtful Accounts
	Year ended December 31, 2013	$	7,617	$	7,787	$	(7,763	)	$	7,640
	Year ended December 31, 2012	$	9,889	$	11,912	$	(14,184	)	$	7,617
	Year ended December 31, 2011	$	11,779	$	12,080	$	(13,970	)	$	9,889

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies	'
Principles of Consolidation	'
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company's financial instruments consist mainly of cash and cash equivalents, accounts receivable, other current assets, accounts payable, deferred revenue and other current liabilities. The carrying value of these financial instruments approximates their fair value because of their short-term nature. The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash and have insignificant interest rate risk.
Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable related to the patient services segment are recorded at the time revenue is recognized, net of contractual allowances, and are presented on the balance sheet net of allowance for doubtful accounts. The ultimate collection of accounts receivable may not be known for several months after services have been provided and billed. The Company records bad debt expense based on the aging of receivables using historical company specific data. The percentages and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections, and the aging of specific receivables. Because of continuing changes in the health care industry and third party reimbursement, it is possible that the Company's estimates of collectability could change, which could have a material impact on the Company's operations and cash flows.
	Accounts receivable related to the product and research services segments are recorded at the time revenue is recognized, or when the services or products are billable, net of discounts. The Company estimates allowance for doubtful accounts on a specific account basis, and considers several factors in its analysis including customer specific information and aging of the account.
	The Company writes off receivables when the likelihood for collection is remote and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The Company performs write-offs on a monthly basis. In the patient services segment, the Company wrote off $7,919 and $14,184 of receivables for the years ended December 31, 2013 and 2012, respectively. The impact was a reduction of gross receivables and a reduction in the allowance for doubtful accounts. Additionally, the Company recorded bad debt expense of $7,787, $11,912 and $12,080 for the years ended December 31, 2013, 2012 and 2011, respectively. Based on collection experience, unfavorable adjustments of $1,480 and $6,343 were made to accounts receivable in 2013 and 2012, respectively, related to prior years accounts receivable. There were no write-offs in the product and research services segments.
Concentrations of Credit Risk	'
	Concentrations of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents with high quality financial institutions to mitigate this risk. The Company performs ongoing credit evaluations of its customers and generally does not require collateral. The Company records an allowance for doubtful accounts in accordance with the procedures described above. Past-due amounts are written off against the allowance for doubtful accounts when collections are believed to be unlikely and all collection efforts have ceased.
	At December 31, 2013, 2012 and 2011, one customer, Medicare, accounted for 18%, 20% and 19%, respectively, of the Company's net accounts receivable.
Inventory	'
	Inventory
	Inventory is valued at the lower of cost (using first-in, first-out cost method) or market (net realizable value or replacement cost). Company management periodically reviews inventory for specific future usage, and estimates of impairment of individual inventory items are recorded to reduce inventory to the lower of cost or market.
Property and Equipment	'
	Property and Equipment
	Property and equipment is recorded at cost. Depreciation is recorded over the estimated useful life of each class of depreciable assets, and is computed using the straight-line method. Leasehold improvements are amortized over the shorter of the estimated asset life or term of the lease. Repairs and maintenance costs are charged to expense as incurred.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company periodically evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in Accounting Standards Codification (ASC) 360, Property, Plant & Equipment. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of these assets in relation to the operating performance of the business and the undiscounted cash flows expected to result from the use of these assets. Impairment losses are recognized when the sum of the expected future cash flows is less than the assets' carrying value.
Goodwill and Acquired Intangible Assets	'
	Goodwill and Acquired Intangible Assets
	Goodwill is the excess of purchase price of an acquired business over the amounts assigned to assets acquired and liabilities assumed in a business combination. In accordance with ASC 350, Intangibles—Goodwill and Other, goodwill is reviewed for impairment annually, or when events arise that could indicate that impairment exists. The provisions of ASC 350 require that the Company perform a two-step impairment test. In the first step, the Company compares the fair value of its reporting units to the carrying value of the reporting units. If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units' goodwill. If the carrying value of the reporting units' goodwill exceeds its implied fair value, an impairment loss equal to the difference is recorded.
	For the purpose of performing its goodwill impairment analysis in 2013, the Company considers its business to be comprised of three reporting units, patient services, product and research services. The Company calculates the fair value of the reporting units utilizing the income and market approaches. The income approach is based on a discounted cash flow methodology that includes assumptions for, among other things, forecasted income, cash flow, growth rates, income tax rates, expected tax benefits and long-term discount rates, all of which require significant judgment. The market approach utilizes the Company's market data. There are inherent uncertainties related to these factors and the judgment applied in the analysis. The Company believes that the combination of an income and a market approach provides a reasonable basis to estimate the fair value of its reporting units.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes approximately 78% of its total revenue from patient monitoring services in its patient services segment, derived from its MCOT™, wEvent, event, Holter, Pacemaker and INR services. The Company receives a significant portion of its revenue from third party commercial payors and governmental entities. It also receives reimbursement directly from patients through co-pay, deductibles and self-pay arrangements.
	Revenue from the Medicare program is based on reimbursement rates set by CMS. Revenue from contracted commercial payors is recorded at the negotiated contractual rate. Revenue from non-contracted commercial payors is recorded at net realizable value based on historical payment patterns. Adjustments to the estimated net realizable value, based on final settlement with the third party payors, are recorded upon settlement. If the Company does not have consistent historical information regarding collectability from a given payor, revenue is recognized when cash is received. Unearned amounts are appropriately deferred until service is performed. For the years ended December 31, 2013, 2012 and 2011, revenue from Medicare as a percentage of total Company revenue was 35%, 37% and 33%, respectively.
	Revenue received from the sale of products, product repair and supplies is recognized when shipped, or as service is completed. Unearned amounts are appropriately deferred until service is performed.
	Research services revenue includes revenue for research and core laboratory services. The Company's research services revenues are provided on a fee for service basis, and revenue is recognized as the related services are performed. We also provide consulting services on a time and materials basis and recognize revenues as we perform the services. Our site support revenue, consisting of equipment rentals and sales along with related supplies and logistics management, are recognized at the time of sale or over the rental period. Under a typical contract, customers pay us a portion of our fee for these services upon contract execution as an upfront deposit, some of which is typically nonrefundable upon contract termination. Unearned revenues are deferred, and then recognized as the services are performed.
	For arrangements with multiple deliverables, the revenue is allocated to each element (both delivered and undelivered items) based on their relative selling prices or management's best estimate of their selling prices, when vendor-specific or third-party evidence is unavailable.
	We record reimbursements received for out-of-pocket expenses, including freight, incurred as revenue in the accompanying consolidated statements of operations. Revenue generally is recognized net of any taxes collected from customers and subsequently remitted to government authorities.
Advertising Costs	'
	Advertising Costs
	Advertising costs are charged to expense as incurred. For the years ended December 31, 2013, 2012 and 2011, the Company incurred advertising costs of $223, $174 and $218, respectively.
Research and Development Costs	'
	Research and Development Costs
	Research and development costs are charged to expense as incurred.
Net Loss	'
	Net Loss
	The Company computes net loss per share in accordance with ASC 260, Earnings Per Share. Basic net loss per share is computed by dividing net loss per share available to common shareholders by the weighted average number of common shares outstanding for the period, and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the treasury stock or if converted methods, as applicable.
	The following summarizes the potential outstanding common stock of the Company as of the end of each period:
		December 31,			December 31,			December 31,
		2013			2012			2011
	Employee stock purchase plan estimated share options outstanding		81,848			50,903			51,544
	Common stock options and restricted stock units ("RSUs") outstanding		3,993,590			3,669,103			2,468,991
	Common stock options available for grant		2,404,498			1,853,786			2,369,802
	Common stock		25,812,754			25,189,340			24,534,601
	Total		32,292,690			30,763,132			29,424,938
	Basic net loss per share is computed by dividing net loss by the weighted average number of fully vested common shares outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common shares, including stock options, and RSUs.
	The following table presents the calculation of historical basic and diluted net loss per share:
		Year Ended December 31,
		2013			2012			2011
		(in thousands, except per share amounts)
	Numerator:
	Net loss	$	(7,319	)	$	(12,202	)	$	(61,422	)
	Denominator:
	Weighted average shares used in computing basic and diluted net loss per share		25,543,646			24,933,656			24,425,318
	Basic and diluted net loss per share	$	(0.29	)	$	(0.49	)	$	(2.51	)
Stock-Based Compensation	'
	Stock-Based Compensation
	ASC 718, Compensation—Stock Compensation, addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments of the enterprise or (b) liabilities that are based on the fair value of the enterprise's equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires that an entity measures the cost of equity-based service awards based on the grant-date fair value of the award and recognizes the cost of such awards over the period during which the employee is required to provide service in exchange for the award (the vesting period). ASC 718 requires that an entity measures the cost of liability-based service awards based on current fair value that is re-measured subsequently at each reporting date through the settlement date. The Company accounts for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes under the liability method, as described in ASC 740, Income Taxes. Deferred income taxes are recognized for the tax consequences of temporary differences between the tax and financial statement reporting bases of assets and liabilities. A valuation allowance for net deferred tax assets is provided unless realizability is judged by the Company to be more likely than not.
Segment Information	'
	Segment Information
	ASC 280, Segment Reporting, establishes standards for reporting information regarding operating segments in annual financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker, or decision-making group in making decisions on how to allocate resources and assess performance.
	Effective in the third quarter 2012, with the acquisition of Cardiocore, the Company changed its reportable segments from two segments: patient services and product, to three segments: patient services, product and research services. The patient services business segment's principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient TelemetryTM (MCOTTM), wEvent, event, Holter and Pacemaker services, as well as INR services in a healthcare setting. The Product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Research services segment includes the Company's operations that engage in central core laboratory services in a research environment, which includes certain equipment rental and product sales. In addition, the Company realigned the Product segment to exclude central core laboratory research operations previously reported in this segment and repositioned these operations into the Research services segment. Disclosures for the twelve months ended December 31, 2012 have been adjusted to reflect the change in reportable segments.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In July 2012, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2012-02, Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment. The new guidance allows an entity the option to first assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that the indefinite-lived intangible asset is impaired. If the qualitative assessment leads to the determination that is more likely than not that the indefinite-lived intangible asset is impaired, then the entity is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount. The ASU is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The amendment did not have a material impact on the Company's results of operations, cash flows, or financial position.
	In February 2013, FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. The new guidance requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. The ASU is effective prospectively for reporting periods beginning after December 15, 2012. The amendment did not have a material impact on the Company's results of operations, cash flows, or financial position.
	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The new guidance provides specific financial statement presentation requirements of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance states that an unrecognized tax benefit in those circumstances should be presented as a reduction to the deferred tax asset. The ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company does not expect the amendment to have a material impact on its results of operations, cash flows, or financial position.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies	'
Summary of potential outstanding common stock	'
		December 31,			December 31,			December 31,
		2013			2012			2011
	Employee stock purchase plan estimated share options outstanding		81,848			50,903			51,544
	Common stock options and restricted stock units ("RSUs") outstanding		3,993,590			3,669,103			2,468,991
	Common stock options available for grant		2,404,498			1,853,786			2,369,802
	Common stock		25,812,754			25,189,340			24,534,601
	Total		32,292,690			30,763,132			29,424,938
Schedule of calculation of historical basic and diluted net loss per share	'
		Year Ended December 31,
		2013			2012			2011
		(in thousands, except per share amounts)
	Numerator:
	Net loss	$	(7,319	)	$	(12,202	)	$	(61,422	)
	Denominator:
	Weighted average shares used in computing basic and diluted net loss per share		25,543,646			24,933,656			24,425,318
	Basic and diluted net loss per share	$	(0.29	)	$	(0.49	)	$	(2.51	)

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2013
Business Acquisition	'
Schedule of unaudited pro forma information representing combined results of operations as if the acquisition had occurred at the beginning of the periods presented	'
		December 31,
		2012			2011
	Revenue	$	124,698		$	134,102
	Net Income (Loss)	$	(10,936	)	$	(62,712	)
	Net Income per common share:
	Basic and Diluted	$	(0.47	)	$	(2.56	)
	Weighted average number of shares:
	Basic		24,933,656			24,425,318
ECG Scanning	'
Business Acquisition	'
Schedule of preliminary purchase price allocation	'
	The purchase price allocation of the ECG Scanning acquisition purchase consideration of $6,370 was completed in the second quarter of 2012. The following table summarizes the purchase price allocation:
	Fair value of assets acquired:
	Cash and cash equivalents	$	32
	Accounts receivable		1,686
	Prepaid expenses and other current assets		141
	Property and equipment		2,655
	Goodwill		1,577
	Intangible assets		1,540
	Other assets		64
	Total assets acquired		7,695
	Liabilities assumed:
	Accounts payable		508
	Accrued expenses		283
	Other liabilities		534
	Total liabilities assumed		1,325
	Net assets acquired	$	6,370
Cardiocore	'
Business Acquisition	'
Schedule of preliminary purchase price allocation	'
	The purchase price allocation of the Cardiocore acquisition purchase consideration of $23,500 was completed in the fourth quarter of 2012. The following table summarizes the purchase price allocation:
	Fair value of assets acquired:
	Cash and cash equivalents	$	1,113
	Accounts receivable		4,290
	Prepaid expenses and other current assets		386
	Property and equipment		4,230
	Goodwill		11,506
	Intangible assets		6,920
	Total assets acquired		28,445
	Liabilities assumed:
	Accounts payable		1,195
	Accrued expenses		1,215
	Deferred tax liabilities		935
	Deferred revenue		1,600
	Total liabilities assumed		4,945
	Net assets acquired	$	23,500

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory	'
Schedule of inventory	'
		December 31,
		2013		2012
	Raw materials and supplies	$	2,404	$	2,782
	Finished goods		150		112
	Total inventories	$	2,554	$	2,894

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property and Equipment	'
Schedule of Property and equipment	'
			December 31,
		Estimated
		Useful Life
		(Years)	2013			2012
	Cardiac monitoring devices, device parts and components	3 - 5	$	37,273		$	52,943
	Computers and purchased software	3 - 5		13,302			12,088
	Equipment, tools and molds	3		5,384			6,591
	Furniture and fixtures	3		2,863			3,476
	Leasehold improvements	Life of lease		2,665			5,828
	Capital leases	5		737			—
	Total property and equipment, at cost			62,224			80,926
	Less accumulated depreciation			(43,445	)		(61,075	)
	Total property and equipment, net		$	18,779		$	19,851

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets	'
Schedule of changes in the carrying amounts of goodwill by segment	'
		Reporting Segment
		Patient			Research			Product		Total
		Services			Services
	Balance at December 31, 2012	$	1,577		$	11,712		$	3,157	$	16,446
	Goodwill acquired during the year		—			23			—		23
	Balance at December 31, 2013	$	1,577		$	11,735		$	3,157	$	16,469
Schedule of gross carrying amounts and accumulated amortization of the entity's intangible assets	'
				December 31,
		Estimated
		Useful Life
		(Years)		2013			2012
	Customer relationships	6 - 10		$	2,100		$	3,651
	Proprietary technology	5			4,000			4,000
	Signed backlog	1 - 4			2,800			2,800
	Unsigned backlog	4			600			600
	Covenants not to compete	5			360			360
	Total intangible assets, gross				9,860			11,411
	Customer relationships accumulated amortization				(722	)		(1,894	)
	Proprietary technology accumulated amortization				(1,902	)		(676	)
	Signed backlog accumulated amortization				(1,400	)		(875	)
	Unsigned backlog accumulated amortization				(200	)		(50	)
	Covenants not to compete accumulated amortization				(124	)		(52	)
	Total accumulated amortization				(4,348	)		(3,547	)
	Indefinite-lived trade name				1,800			1,800
	Total intangible assets, net			$	7,312		$	9,664
Summary of estimated amortization expense for the next five years	'
	The estimated amortization expense for the next five years is summarized as follows at December 31, 2013:
	2014	$	2.294
	2015		1,938
	2016		842
	2017		138
	2018		100
	Total	$	5,312

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Expenses	'
Schedule of accrued expenses	'
		December 31,
		2013		2012
	Accrued compensation	$	4,932	$	6,382
	Accrued professional fees		1,922		544
	Accrued purchases		311		197
	Accrued restructuring costs		96		914
	Other		929		1,909
	Total	$	8,190	$	9,946

Integration_Restructuring_and_1

Integration, Restructuring and Other Charges (Tables)	12 Months Ended
	Dec. 31, 2013
Integration, Restructuring and Other Charges	'
Summary of expenses related to restructuring, integration and other activities	'
	For the year ended December 31, 2013, the Company incurred expenses related to restructuring, integration and other activities. A summary of these expenses is as follows:
	Legal fees	$	5,516
	Severance and employee related costs		1,410
	Expenses related to facility closure		564
	Professional fees		492
	Total	$	7,982
	For the year ended December 31, 2012, the Company incurred expenses related to restructuring, integration and other activities. A summary of these expenses is as follows:
	Legal fees	$	1,780
	Severance and employee related costs		1,490
	Professional fees		778
	Other charges		188
	Total	$	4,236
	For the year ended December 31, 2011, the Company incurred expenses related to restructuring, integration and other activities. A summary of these expenses is as follows:
	Legal fees	$	2,835
	Biotel integration		1,023
	Professional fees		639
	Other charges		162
	Total	$	4,659

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Shareholders' Equity	'
Summary of option and RSU activity under all equity incentive plans	'
					Options/RSU's Outstanding
		Shares			Number			Weighted
		Available			of Shares			Average
		for Grant						Exercise Price
	Balance—December 31, 2010		1,649,723			2,102,376		$	12.18
	Additional shares authorized for grant		1,207,210			—			—
	Granted		(724,333	)		724,333		$	4.67
	Cancelled/forfeited		237,202			(237,202	)	$	15.1
	Exercised/vesting		—			(120,516	)	$	7.78
	Balance—December 31, 2011		2,369,802			2,468,991		$	9.43
	Additional shares authorized for grant		1,216,611			—			—
	Granted		(2,128,939	)		2,128,939		$	2.73
	Cancelled/forfeited		396,312			(396,312	)	$	9.98
	Exercised/vesting		—			(532,515	)	$	7.85
	Balance—December 31, 2012		1,853,786			3,669,103		$	5.83
	Additional shares authorized for grant		1,260,768			—			—
	Granted		(1,186,639	)		1,186,639		$	3.35
	Cancelled/forfeited		476,583			(476,583	)	$	5.41
	Exercised/vesting		—			(385,569	)	$	4.6
	Balance—December 31, 2013		2,404,498			3,993,590		$	5.25
Summary of total outstanding stock options	'
	A summary of total outstanding stock options as of December 31, 2013 is as follows:
		Options Outstanding									Options Exercisable
	Range of Exercise	Number			Weighted-			Weighted-			Number		Weighted-		Weighted-
	Price	Outstanding			Average			Average			Exercisable		Average		Average
					Remaining			Exercise Price					Remaining		Exercise Price
					Contractual								Contractual
					Life (in years)								Life (in years)
	$0.70 - $7.50		2,715,216			7.81		$	3.82			1,279,892		7.24	$	4.52
	$7.51 - $15.00		90,796			8.17		$	9.5			34,546		5.59	$	9.23
	$15.01 - $22.50		249,522			5.28		$	18.4			249,522		5.28	$	18.4
	$22.51 - $31.18		80,400			4.62		$	30.17			80,400		4.62	$	30.17
	$0.70 - $31.18		3,135,934			7.54		$	5.82			1,644,360		6.78	$	7.98
Summary of total outstanding RSU's	'
	In addition, a summary of total outstanding RSU's as of December 31, 2013 is as follows:
	Range of Grant Price	RSU's
		Outstanding
	$2.16 - $6.75		844,943
	$6.76 - $9.75		12,713
	$2.16 - $9.75		857,656
Summary of certain additional information with respect to options	'
	(In thousands)	2013			2012			2011
	Aggregate intrinsic value of options outstanding at year-end	$	11,183		$	46		$	17
	Aggregate intrinsic value of options exercisable at year-end		4,382			13			17
	Aggregate intrinsic value of options exercised during the year		422			2			7
Schedule of shares of common stock reserved for issuance	'
		December 31,
		2013			2012			2011
	Exercise of options available and grants of awards under equity plans		6,398,088			5,522,889			4,838,793
Schedule of weighted average assumptions used to estimate the fair value of the stock-based awards	'
		Year Ended
		December 31,
		2013			2012			2011
	Expected volatility		60.3	%		63.4	%		62	%
	Expected term (in years)		6.71			6.31			6.25
	Weighted-average risk-free interest rate		1.34	%		1.15	%		2.48	%
	Expected dividends		0	%		0	%		0	%
	Weighted-average grant date fair value per share	$	1.9		$	1.58		$	2.82
Summary of the status of unvested stock options and RSU's as of the respective balance sheet dates and changes during years	'
		Number of			Weighted-
		Shares			Average
					Grant-Date
					Fair Value
					(per share)
	Unvested shares at December 31, 2012		2,436,702		$	2.62
	Granted		1,186,639		$	2.52
	Vested		(797,528	)	$	3.14
	Cancelled/forfeited		(476,583	)	$	3.49
	Unvested shares at December 31, 2013		2,349,230		$	2.45

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Schedule of the components of the entity's deferred tax assets and liabilities	'
		December 31,
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards	$	37,335		$	37,384
	Research & development and AMT credit carryforwards		4,687			4,530
	Stock option grants		6,533			5,329
	Allowance for doubtful accounts		3,101			2,932
	Other, net		1,928			2,210
	Total deferred tax assets		53,584			52,385
	Less valuation allowance		(50,979	)		(49,145	)
	Net deferred tax assets	$	2,605		$	3,240
	Deferred tax liabilities:
	Property, plant and equipment		(345	)		(815	)
	Identified intangible assets		(2,089	)		(2,404	)
	Indefinite lived intangible assets		(730	)		(678	)
	Prepaid insurance		(171	)		(21	)
	Total deferred tax liabilities		(3,335	)		(3,918	)
	Net deferred tax liability		(730	)		(678	)
Schedule of reconciliations between expected income taxes computed at the federal rate and the provision (benefit) for income taxes	'
		Years ended December 31,
		2013			2012			2011
	Income tax benefit at statutory rate	$	(2,486	)	$	(4,587	)	$	(21,412	)
	State income tax, net of federal benefit		716			(211	)		191
	Stock-based compensation		203			397			493
	Nondeductible goodwill impairment		—			—			16,100
	Other		182			200			(173	)
	Increase in valuation allowance		1,600			3,296			5,045
	Income tax provision (benefit)	$	215		$	(905	)	$	244
Schedule of the components of the entity's income tax (benefit) provision	'
		Year Ended
		December 31,
		2013			2012
	Current:
	Federal	$	24		$	—
	State		138			128
	Total current provision for income taxes		162			128
	Deferred:
	Federal		—			(996	)
	State		53			(37	)
	Total deferred provision (benefit) for income taxes		53			(1,033	)
	Total provision (benefit) for income taxes	$	215		$	(905	)

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies	'
Summary of the future minimum lease payments under non-cancelable operating and capital leases	'
	Future minimum lease payments under non-cancelable operating and capital leases are summarized as follows at December 31, 2013:
		Operating		Capital
		Leases		Leases
	2014	$	2,250	$	205
	2015		2,195		205
	2016		1,881		205
	2017		1,749		103
	2018		1,732		—
	Thereafter		2,227		—
		$	12,034	$	718

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Information	'
Summary of financial information concerning the entity's reportable segments	'
		Patient		Research		Product		Corporate			Consolidated
		Services		Services				and Other
	2013
	Revenues	$	100,386	$	20,329	$	8,786	$	—		$	129,501
	Intersegment revenues		—		—		6,191		(6,191	)		—
	Income (loss) before income taxes		27,298		798		5,307		(40,507	)		(7,104	)
	Depreciation and amortization		4,253		4,057		551		3,457			12,318
	Capital expenditures		5,796		2,242		131		—			8,169
		Patient		Research		Product		Corporate			Consolidated
		Services		Services				and Other
	2012
	Revenues	$	93,640	$	8,333	$	9,521	$	—		$	111,494
	Intersegment revenues		—		—		2,141		(2,141	)		—
	Income (loss) before income taxes		13,284		1,556		3,770		(31,717	)		(13,107	)
	Depreciation and amortization		5,161		974		428		2,815			9,378
	Capital expenditures		4,199		1,079		684		—			5,962

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Data (Unaudited)	'
Summary of the unaudited quarterly financial data	'
		First			Second			Third			Fourth
		Quarter			Quarter			Quarter			Quarter
		(in thousands, except per share amount)
	2013
	Total revenues	$	32,418		$	32,104		$	31,874		$	33,105
	Gross profit		19,545			19,496			19,234			20,795
	Integration, restructuring and other charges		1,202			2,541			3,077			1,162
	Income (loss) from operations		(2,034	)		(2,238	)		(2,835	)		226
	Net income (loss)		(2,087	)		(2,299	)		(2,956	)		23
	Basic and diluted net income (loss) per share	$	(0.08	)	$	(0.09	)	$	(0.12	)	$	0
	2012
	Total revenues	$	27,045		$	27,450		$	27,040		$	29,959
	Gross profit		15,610			16,726			16,398			17,167
	Integration, restructuring and other charges		270			733			741			2,492
	Loss from operations		(3,581	)		(1,668	)		(3,126	)		(4,784	)
	Net loss		(3,534	)		(1,198	)		(3,121	)		(4,349	)
	Basic and diluted net loss per share	$	(0.14	)	$	(0.05	)	$	(0.12	)	$	(0.17	)

Organization_and_Description_o1

Organization and Description of Business (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2011
	segment	segment
Organization and Description of Business	'	'
Number of operating segments	3	2

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounts receivable and allowance for doubtful accounts	'	'	'
Write-off of receivables	$7,919	$14,184	'
Bad debt expense	7,787	11,912	12,080
Unfavorable adjustments related to prior year's accounts receivable	1,480	6,343	'
Product and research services segments	'	'	'
Accounts receivable and allowance for doubtful accounts	'	'	'
Write-off of receivables	$0	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 2) (Net accounts receivable, Credit concentration risk, Medicare)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	customer
Net accounts receivable | Credit concentration risk | Medicare	'	'	'
Concentrations of credit risk	'	'	'
Number of major customers	1	'	'
Concentration risk (as a percent)	18.00%	20.00%	19.00%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 3)	0 Months Ended	3 Months Ended	12 Months Ended
	Sep. 29, 2012	Sep. 30, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	segment	segment	segment	Revenue	Revenue	Revenue	Revenue
				Service concentration	Payor concentration	Payor concentration	Payor concentration
				Patient monitoring services	Medicare	Medicare	Medicare
Goodwill and Acquired Intangible Assets	'	'	'	'	'	'	'
Number of reporting units	2	3	3	'	'	'	'
Revenue Recognition	'	'	'	'	'	'	'
Concentration risk (as a percent)	'	'	'	78.00%	35.00%	37.00%	33.00%

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 4) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Sep. 29, 2012

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

segment

segment

segment

Advertising Costs

'

'

'

'

'

'

'

'

'

'

'

'

'

Advertising costs incurred

'

'

'

'

'

'

'

'

'

$223

$174

$218

'

Potential outstanding common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee stock purchase plan estimated share options outstanding (in shares)

'

81,848

'

'

'

50,903

'

'

'

81,848

50,903

51,544

'

Common stock options and restricted stock units ("RSUs") outstanding (in shares)

'

3,993,590

'

'

'

3,669,103

'

'

'

3,993,590

3,669,103

2,468,991

'

Common stock options available for grant (in shares)

'

2,404,498

'

'

'

1,853,786

'

'

'

2,404,498

1,853,786

2,369,802

1,649,723

Common stock (in shares)

'

25,812,754

'

'

'

25,189,340

'

'

'

25,812,754

25,189,340

24,534,601

'

Total (in shares)

'

32,292,690

'

'

'

30,763,132

'

'

'

32,292,690

30,763,132

29,424,938

'

Calculation of historical basic and diluted net loss per share

'

'

'

'

'

'

'

'

'

'

'

'

'

Numerator: Net loss (in dollars)

'

$23

($2,956)

($2,299)

($2,087)

($4,349)

($3,121)

($1,198)

($3,534)

($7,319)

($12,202)

($61,422)

'

Denominator: Weighted average shares used in computing basic and diluted net loss per share

'

'

'

'

'

'

'

'

'

25,543,646

24,933,656

24,425,318

'

Basic and diluted net loss per share (in dollars per share)

'

$0

($0.12)

($0.09)

($0.08)

($0.17)

($0.12)

($0.05)

($0.14)

($0.29)

($0.49)

($2.51)

'

Segment Information

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of reportable segments

2

'

'

'

'

'

3

'

'

3

'

'

'

Business_Combinations_Details

Business Combinations (Details) (USD $)	12 Months Ended			0 Months Ended		0 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Feb. 10, 2012	Dec. 31, 2012	Aug. 29, 2012
				ECG Scanning	ECG Scanning	Cardiocore
Business Acquisition	'	'	'	'	'	'
Aggregate cash purchase price	'	'	'	$5,800	'	$23,500
Additional cash to be paid upon the achievement of certain performance targets	'	'	'	600	'	'
Estimated fair value	'	'	'	570	0	'
Period for achievement of performance target upon which cash is required to be paid	'	'	'	'1 year	'	'
Fair value of assets acquired:	'	'	'	'	'	'
Cash and cash equivalents	'	'	'	32	'	1,113
Accounts receivable	'	'	'	1,686	'	4,290
Prepaid expenses and other current assets	'	'	'	141	'	386
Property and equipment	'	'	'	2,655	'	4,230
Goodwill	16,446	'	16,469	1,577	'	11,506
Intangible assets	'	'	'	1,540	'	6,920
Other assets	'	'	'	64	'	'
Total assets acquired	'	'	'	7,695	'	28,445
Liabilities assumed:	'	'	'	'	'	'
Accounts payable	'	'	'	508	'	1,195
Accrued expenses	'	'	'	283	'	1,215
Deferred tax liabilities	'	'	'	'	'	935
Deferred revenue	'	'	'	'	'	1,600
Other liabilities	'	'	'	534	'	'
Total liabilities assumed	'	'	'	1,325	'	4,945
Net assets acquired	'	'	'	6,370	'	23,500
Pro-Forma Information	'	'	'	'	'	'
Revenue	124,698	134,102	'	'	'	'
Net Income (Loss)	($10,936)	($62,712)	'	'	'	'
Net Income per common share: Basic and Diluted (in dollars per share)	($0.47)	($2.56)	'	'	'	'
Weighted average number of shares: Basic	24,933,656	24,425,318	'	'	'	'

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory	'	'
Raw materials and supplies	$2,404	$2,782
Finished goods	150	112
Total inventories	$2,554	$2,894

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property and equipment	'	'	'
Total property and equipment, at cost	$62,224	$80,926	'
Less accumulated depreciation	-43,445	-61,075	'
Total property and equipment, net	18,779	19,851	'
Depreciation expense	9,978	8,037	10,913
Cardiac monitoring devices, device parts and components	'	'	'
Property and equipment	'	'	'
Total property and equipment, at cost	37,273	52,943	'
Cardiac monitoring devices, device parts and components | Minimum	'	'	'
Property and equipment	'	'	'
Estimated Useful Life	'3 years	'	'
Cardiac monitoring devices, device parts and components | Maximum	'	'	'
Property and equipment	'	'	'
Estimated Useful Life	'5 years	'	'
Computers and purchased software	'	'	'
Property and equipment	'	'	'
Total property and equipment, at cost	13,302	12,088	'
Computers and purchased software | Minimum	'	'	'
Property and equipment	'	'	'
Estimated Useful Life	'3 years	'	'
Computers and purchased software | Maximum	'	'	'
Property and equipment	'	'	'
Estimated Useful Life	'5 years	'	'
Equipment, tools and molds	'	'	'
Property and equipment	'	'	'
Estimated Useful Life	'3 years	'	'
Total property and equipment, at cost	5,384	6,591	'
Furniture and fixtures	'	'	'
Property and equipment	'	'	'
Estimated Useful Life	'3 years	'	'
Total property and equipment, at cost	2,863	3,476	'
Leasehold improvements	'	'	'
Property and equipment	'	'	'
Total property and equipment, at cost	2,665	5,828	'
Capital leases	'	'	'
Property and equipment	'	'	'
Estimated Useful Life	'5 years	'	'
Total property and equipment, at cost	$737	'	'

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Details) (USD $)	12 Months Ended			12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
		Patient Services	Patient Services	Research Services	Product	Product
Changes in the carrying amounts of goodwill by segment	'	'	'	'	'	'
Balance at the beginning of the period	$16,446	$1,577	$1,577	$11,712	$3,157	$3,157
Goodwill acquired during the year	23	'	'	23	'	'
Balance at the end of the period	$16,469	$1,577	$1,577	$11,735	$3,157	$3,157

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Finite lived intangible assets	'	'	'
Total intangible assets, gross	$9,860	$11,411	'
Total accumulated amortization	-4,348	-3,547	'
Indefinite-lived trade name	1,800	1,800	'
Total intangible assets, net	7,312	9,664	'
Estimated amortization expenses	'	'	'
2014	2,294	'	'
2015	1,938	'	'
2016	842	'	'
2017	138	'	'
2018	100	'	'
Total	5,312	'	'
Amortization expense	2,340	1,341	1,219
Goodwill impairment charge	'	'	45,999
Customer relationships	'	'	'
Finite lived intangible assets	'	'	'
Total intangible assets, gross	2,100	3,651	'
Total accumulated amortization	-722	-1,894	'
Customer relationships | Minimum	'	'	'
Finite lived intangible assets	'	'	'
Estimated Useful Life	'6 years	'	'
Customer relationships | Maximum	'	'	'
Finite lived intangible assets	'	'	'
Estimated Useful Life	'10 years	'	'
Proprietary technology	'	'	'
Finite lived intangible assets	'	'	'
Estimated Useful Life	'5 years	'	'
Total intangible assets, gross	4,000	4,000	'
Total accumulated amortization	-1,902	-676	'
Signed backlog	'	'	'
Finite lived intangible assets	'	'	'
Total intangible assets, gross	2,800	2,800	'
Total accumulated amortization	-1,400	-875	'
Signed backlog | Minimum	'	'	'
Finite lived intangible assets	'	'	'
Estimated Useful Life	'1 year	'	'
Signed backlog | Maximum	'	'	'
Finite lived intangible assets	'	'	'
Estimated Useful Life	'4 years	'	'
Unsigned backlog	'	'	'
Finite lived intangible assets	'	'	'
Estimated Useful Life	'4 years	'	'
Total intangible assets, gross	600	600	'
Total accumulated amortization	-200	-50	'
Covenants not to compete	'	'	'
Finite lived intangible assets	'	'	'
Estimated Useful Life	'5 years	'	'
Total intangible assets, gross	360	360	'
Total accumulated amortization	($124)	($52)	'

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Expenses	'	'
Accrued compensation	$4,932	$6,382
Accrued professional fees	1,922	544
Accrued purchases	311	197
Accrued restructuring costs	96	914
Other	929	1,909
Total	$8,190	$9,946

Integration_Restructuring_and_2

Integration, Restructuring and Other Charges (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Integration, Restructuring and Other Charges	'	'	'	'	'	'	'	'	'	'	'
Legal fees	'	'	'	'	'	'	'	'	$5,516	$1,780	$2,835
Severance and employee related costs	'	'	'	'	'	'	'	'	1,410	1,490	'
Expenses related to facility closure	'	'	'	'	'	'	'	'	564	'	'
Professional fees	'	'	'	'	'	'	'	'	492	778	639
Other charges	'	'	'	'	'	'	'	'	'	188	162
Total	1,162	3,077	2,541	1,202	2,492	741	733	270	7,982	4,236	4,659
Biotel | Severance and employee related costs	'	'	'	'	'	'	'	'	'	'	'
Integration, Restructuring and Other Charges	'	'	'	'	'	'	'	'	'	'	'
Integration costs	'	'	'	'	'	'	'	'	'	'	$1,023

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	12 Months Ended							0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Mar. 18, 2008	Mar. 18, 2008
				Stock options	Stock options	Stock options	Stock options	Stock options	Non-statutory options
				2008 Option Plan	2008 Option Plan	Directors' Plan	Directors' Plan	2003 Option Plan	2003 Option Plan
					Maximum		Maximum		Minimum
Shareholders' Equity	'	'	'	'	'	'	'	'	'
Common stock, shares authorized	200,000,000	200,000,000	'	'	'	'	'	'	'
Common stock, shares outstanding	25,812,754	25,189,340	24,534,601	'	'	'	'	'	'
Preferred stock, shares authorized	0	0	'	'	'	'	'	'	'
Preferred stock, shares outstanding	0	0	'	'	'	'	'	'	'
Stock-based compensation	'	'	'	'	'	'	'	'	'
Increase in the number of options available to be granted as a percentage of total number of common shares outstanding	'	'	'	4.00%	'	'	'	'	'
Increase in the number of options available to be granted (in shares)	'	'	'	1,500,000	'	'	'	'	'
Expiration period	'	'	'	'	'10 years	'	'10 years	'10 years	'
Percentage of awards vesting on the first anniversary of the grant date	'	'	'	'	'	'	'	25.00%	'
Percentage of initial and committee chair grants vesting on the first anniversary of the grant date	'	'	'	'	'	33.00%	'	'	'
Period after the first anniversary of the grant date in which awards vest ratably	'	'	'	'	'	'	'	'36 months	'
Period after the first anniversary of the grant date in which the initial and committee chair grants vest ratably	'	'	'	'	'	'24 months	'	'	'
Period over which annual grants vest	'	'	'	'	'	'	'12 months	'	'
Purchase price as a percentage of the fair market value	'	'	'	'	'	'	'	'	85.00%
Shares Available for Grant	'	'	'	'	'	'	'	'	'
Balance at the beginning of the period (in shares)	1,853,786	2,369,802	1,649,723	'	'	'	'	'	'
Additional shares authorized for grant	1,260,768	1,216,611	1,207,210	'	'	'	'	'	'
Granted (in shares)	-1,186,639	-2,128,939	-724,333	'	'	'	'	'	'
Cancelled/forfeited (in shares)	476,583	396,312	237,202	'	'	'	'	'	'
Balance at the end of the period (in shares)	2,404,498	1,853,786	2,369,802	'	'	'	'	'	'
Number of Shares	'	'	'	'	'	'	'	'	'
Balance at the beginning of the period (in shares)	3,669,103	2,468,991	2,102,376	'	'	'	'	'	'
Granted (in shares)	1,186,639	2,128,939	724,333	'	'	'	'	'	'
Cancelled/forfeited (in shares)	-476,583	-396,312	-237,202	'	'	'	'	'	'
Exercised/vesting (in shares)	-385,569	-532,515	-120,516	'	'	'	'	'	'
Balance at the end of the period (in shares)	3,993,590	3,669,103	2,468,991	'	'	'	'	'	'
Weighted Average Exercise Price	'	'	'	'	'	'	'	'	'
Balance at the beginning of the period (in dollars per share)	$5.83	$9.43	$12.18	'	'	'	'	'	'
Granted (in dollars per share)	$3.35	$2.73	$4.67	'	'	'	'	'	'
Cancelled/forfeited (in dollars per share)	$5.41	$9.98	$15.10	'	'	'	'	'	'
Exercised/Vesting (in dollars per share)	$4.60	$7.85	$7.78	'	'	'	'	'	'
Balance at the end of the period (in dollars per share)	$5.25	$5.83	$9.43	'	'	'	'	'	'

Shareholders_Equity_Details_2

Shareholders' Equity (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013
$0.70 - $7.50	'
Summary of total outstanding stock options	'
Range of exercise prices, low end of range (in dollars per share)	$0.70
Range of exercise prices, high end of range (in dollars per share)	$7.50
Options Outstanding	'
Number Outstanding (in shares)	2,715,216
Weighted - Average Remaining Contractual Life	'7 years 9 months 22 days
Weighted - Average Exercise Price (in dollars per share)	$3.82
Options Exercisable	'
Number Exercisable (in shares)	1,279,892
Weighted - Average Remaining Contractual Life	'7 years 2 months 26 days
Weighted - Average Exercise Price (in dollars per share)	$4.52
$7.51 - $15.00	'
Summary of total outstanding stock options	'
Range of exercise prices, low end of range (in dollars per share)	$7.51
Range of exercise prices, high end of range (in dollars per share)	$15
Options Outstanding	'
Number Outstanding (in shares)	90,796
Weighted - Average Remaining Contractual Life	'8 years 2 months 1 day
Weighted - Average Exercise Price (in dollars per share)	$9.50
Options Exercisable	'
Number Exercisable (in shares)	34,546
Weighted - Average Remaining Contractual Life	'5 years 7 months 2 days
Weighted - Average Exercise Price (in dollars per share)	$9.23
$15.01 - $22.50	'
Summary of total outstanding stock options	'
Range of exercise prices, low end of range (in dollars per share)	$15.01
Range of exercise prices, high end of range (in dollars per share)	$22.50
Options Outstanding	'
Number Outstanding (in shares)	249,522
Weighted - Average Remaining Contractual Life	'5 years 3 months 11 days
Weighted - Average Exercise Price (in dollars per share)	$18.40
Options Exercisable	'
Number Exercisable (in shares)	249,522
Weighted - Average Remaining Contractual Life	'5 years 3 months 11 days
Weighted - Average Exercise Price (in dollars per share)	$18.40
$22.51 - $31.18	'
Summary of total outstanding stock options	'
Range of exercise prices, low end of range (in dollars per share)	$22.51
Range of exercise prices, high end of range (in dollars per share)	$31.18
Options Outstanding	'
Number Outstanding (in shares)	80,400
Weighted - Average Remaining Contractual Life	'4 years 7 months 13 days
Weighted - Average Exercise Price (in dollars per share)	$30.17
Options Exercisable	'
Number Exercisable (in shares)	80,400
Weighted - Average Remaining Contractual Life	'4 years 7 months 13 days
Weighted - Average Exercise Price (in dollars per share)	$30.17
$0.70 - $31.18	'
Summary of total outstanding stock options	'
Range of exercise prices, low end of range (in dollars per share)	$0.70
Range of exercise prices, high end of range (in dollars per share)	$31.18
Options Outstanding	'
Number Outstanding (in shares)	3,135,934
Weighted - Average Remaining Contractual Life	'7 years 6 months 14 days
Weighted - Average Exercise Price (in dollars per share)	$5.82
Options Exercisable	'
Number Exercisable (in shares)	1,644,360
Weighted - Average Remaining Contractual Life	'6 years 9 months 11 days
Weighted - Average Exercise Price (in dollars per share)	$7.98

Shareholders_Equity_Details_3

Shareholders' Equity (Details 3) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 01, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Stock options

Stock options

Stock options

Stock options

$2.16 - $6.75

$2.16 - $6.75

$2.16 - $6.75

$6.76 - $9.75

$6.76 - $9.75

$6.76 - $9.75

$2.16 - $9.75

$2.16 - $9.75

$2.16 - $9.75

RSU's

Minimum

Maximum

RSU's

Minimum

Maximum

RSU's

Minimum

Maximum

RSU's

RSU's

RSU's

RSU's

RSU's

RSU's

Stock-based compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Grant price (in dollars per share)

'

'

'

'

'

'

'

'

'

$2.16

$6.75

'

$6.76

$9.75

'

$2.16

$9.75

RSU's Outstanding (in shares)

'

'

'

'

'

'

'

'

844,943

'

'

12,713

'

'

857,656

'

'

Aggregate intrinsic value of options outstanding at year-end

'

'

'

'

'

$11,183

$46

$17

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options exercisable at year-end

'

'

'

'

'

4,382

13

17

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options exercised during the year

'

'

'

'

'

422

2

7

'

'

'

'

'

'

'

'

'

Exercise of options available and grants of awards under equity plans (in shares)

6,398,088

5,522,889

4,838,793

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation expense incurred

3,303

3,747

4,006

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impact of stock-based compensation expense on basic and diluted earnings per share (in dollars per share)

($0.13)

($0.15)

($0.16)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total cash received from the exercise of stock options

'

'

'

'

'

467

4

11

'

'

'

'

'

'

'

'

'

Weighted average assumptions used to estimate the fair value of the stock-based awards

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected volatility (as a percent)

60.30%

63.40%

62.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected term

'6 years 8 months 16 days

'6 years 3 months 22 days

'6 years 3 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average risk-free interest rate (as a percent)

1.34%

1.15%

2.48%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected dividend yield (as a percent)

0.00%

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average grant date fair value per share (in dollars per share)

$1.90

$1.58

$2.82

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future forfeiture rate (as a percent)

'

'

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

Total compensation cost of options granted but not yet vested

'

'

'

'

'

2,644

3,433

3,615

'

'

'

'

'

'

'

'

'

Weighted average remaining periods over which unrecognized amounts are expected to be recognized

'2 years 1 month 20 days

'2 years 4 months 2 days

'2 years 7 months 13 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares remained available for future grant under the Plan

2,404,498

1,853,786

2,369,802

1,649,723

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested at the beginning of the period (in shares)

2,436,702

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in shares)

1,186,639

2,128,939

724,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested (in shares)

-797,528

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cancelled/forfeited (in shares)

-476,583

-396,312

-237,202

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested at the end of the period (in share)

2,349,230

2,436,702

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-Average Grant-Date Fair Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested at the beginning of the period (in dollars per share)

$2.62

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in dollars per share)

$2.52

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested (in dollars per share)

$3.14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cancelled/forfeited (in dollars per share)

$3.49

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested at the end of the period (in dollars per share)

$2.45

$2.62

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option Acceleration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Threshold percentage for determining deeply out-of-the-money options

'

'

'

'

30.00%

'

'

'

'

'

'

'

'

'

'

'

'

Number of previously unvested shares, which became fully vested as a result of option acceleration

'

'

'

'

309,000

'

'

'

'

'

'

'

'

'

'

'

'

Expense associated with the accelerated options

'

'

'

'

'

$137

$578

$984

'

'

'

'

'

'

'

'

'

Weighted average exercise price of the accelerated options (in dollars per share)

'

'

'

'

'

$19.87

'

'

'

'

'

'

'

'

'

'

'

Shareholders_Equity_Details_4

Shareholders' Equity (Details 4) (USD $)	12 Months Ended				1 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Jan. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
					Employee Stock Purchase Plan	Employee Stock Purchase Plan	Employee Stock Purchase Plan	Employee Stock Purchase Plan
Stock-based compensation	'	'	'	'	'	'	'	'
Maximum percentage of compensation that employees may contribute through payroll deductions	'	'	'	'	'	15.00%	'	'
Maximum amount that employees may contribute through payroll deductions	'	'	'	'	'	$21	'	'
Percentage of the fair market price on the first day of the offering period or the market price as on the day of purchase	'	'	'	'	'	85.00%	'	'
Common stock purchased (in shares)	'	'	'	'	'	243,185	'	'
Proceeds from the issuance of shares of common stock (in dollars)	'	'	'	'	'	487	'	'
Increase in number of shares available for grant	1,260,768	1,216,611	1,207,210	'	252,154	'	'	'
Number of remaining shares available for purchase	2,404,498	1,853,786	2,369,802	1,649,723	'	517,456	'	'
Expenses incurred	$3,303	$3,747	$4,006	'	'	$211	$182	$201

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred tax assets:	'	'	'
Net operating loss carryforwards	$37,335	$37,384	'
Research & development and AMT credit carryforwards	4,687	4,530	'
Stock option grants	6,533	5,329	'
Allowance for doubtful accounts	3,101	2,932	'
Other, net	1,928	2,210	'
Total deferred tax assets	53,584	52,385	'
Less valuation allowance	-50,979	-49,145	'
Net deferred tax assets	2,605	3,240	'
Deferred tax liabilities:	'	'	'
Property, plant and equipment	-345	-815	'
Identified intangible assets	-2,089	-2,404	'
Indefinite lived intangible assets	-730	-678	'
Prepaid insurance	-171	-21	'
Total deferred tax liabilities	-3,335	-3,918	'
Net deferred tax liability	-730	-678	'
Reconciliation between expected income taxes computed at the federal rate and the provision (benefit) for income taxes	'	'	'
Federal rate of income tax (as a percent)	35.00%	35.00%	35.00%
Income tax benefit at statutory rate	-2,486	-4,587	-21,412
State income tax, net of federal benefit	716	-211	191
Stock-based compensation	203	397	493
Nondeductible goodwill impairment	'	'	16,100
Other	182	200	-173
Increase in valuation allowance	1,600	3,296	5,045
Income tax provision (benefit)	215	-905	244
Net Operating Loss Carryforwards	'	'	'
Minimum percentage of increase in ownership of stockholders for ownership change	50.00%	'	'
Period over which a minimum 50 percent of increase in ownership is required for ownership change	'3 years	'	'
Period of recognition of built-in gains in assets held at the time of ownership change	'5 years	'	'
Current:	'	'	'
Federal	24	'	'
State	138	128	'
Total current provision for income taxes	162	128	'
Deferred:	'	'	'
Federal	'	-996	'
State	53	-37	'
Total deferred provision (benefit) for income taxes	53	-1,033	13
Income tax provision (benefit)	215	-905	244
Tax reserve recorded for tax contingencies	0	0	'
Federal	'	'	'
Net Operating Loss Carryforwards	'	'	'
Net operating loss carryforwards	96,588	'	'
State	'	'	'
Net Operating Loss Carryforwards	'	'	'
Net operating loss carryforwards	$54,243	'	'

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies	'	'	'
Rent expense	$3,622	$2,946	$2,713
Future minimum lease payments under non-cancelable operating leases	'	'	'
2014	2,250	'	'
2015	2,195	'	'
2016	1,881	'	'
2017	1,749	'	'
2018	1,732	'	'
Thereafter	2,227	'	'
Total	12,034	'	'
Future minimum lease payments under capital leases	'	'	'
2014	205	'	'
2015	205	'	'
2016	205	'	'
2017	103	'	'
Total	$718	'	'

Credit_Agreement_Details

Credit Agreement (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Aug. 29, 2012
Credit Agreement	'	'
Loan commitment	'	$15,000
Potential maximum loan commitment	'	$30,000
Variable interest rate basis	'LIBOR	'
Spread on variable interest rate (as a percent)	4.75%	'
Unused line fee (as a percent)	0.50%	'
Loan termination fee (as a percent)	1.00%	'

Employee_Benefit_Plan_Details

Employee Benefit Plan (Details) (USD $)	1 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	31-May-09	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Benefit Plan	'	'	'	'
Employer's matching contribution as a percent of employees' contribution to the plan	100.00%	'	'	'
Employee's contribution to the plan (as a percent)	3.00%	'	'	'
Employer's contribution	'	$0	$0	$1,296

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
									segment		segment
Segment Information	'	'	'	'	'	'	'	'	'	'	'
Number of operating segments	'	'	'	'	'	'	'	'	3	'	2
Segment information	'	'	'	'	'	'	'	'	'	'	'
Revenues	$33,105	$31,874	$32,104	$32,418	$29,959	$27,040	$27,450	$27,045	$129,501	$111,494	$119,022
Income (loss) before income taxes	'	'	'	'	'	'	'	'	-7,104	-13,107	-61,178
Depreciation and amortization	'	'	'	'	'	'	'	'	12,318	9,378	'
Capital expenditures	'	'	'	'	'	'	'	'	8,169	5,962	'
Patient Services	'	'	'	'	'	'	'	'	'	'	'
Segment information	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	100,386	93,640	'
Capital expenditures	'	'	'	'	'	'	'	'	5,796	4,199	'
Research Services	'	'	'	'	'	'	'	'	'	'	'
Segment information	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	20,329	8,333	'
Capital expenditures	'	'	'	'	'	'	'	'	2,242	1,079	'
Product	'	'	'	'	'	'	'	'	'	'	'
Segment information	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	8,786	9,521	'
Capital expenditures	'	'	'	'	'	'	'	'	131	684	'
Operating segments | Patient Services	'	'	'	'	'	'	'	'	'	'	'
Segment information	'	'	'	'	'	'	'	'	'	'	'
Income (loss) before income taxes	'	'	'	'	'	'	'	'	27,298	13,284	'
Depreciation and amortization	'	'	'	'	'	'	'	'	4,253	5,161	'
Operating segments | Research Services	'	'	'	'	'	'	'	'	'	'	'
Segment information	'	'	'	'	'	'	'	'	'	'	'
Income (loss) before income taxes	'	'	'	'	'	'	'	'	798	1,556	'
Depreciation and amortization	'	'	'	'	'	'	'	'	4,057	974	'
Operating segments | Product	'	'	'	'	'	'	'	'	'	'	'
Segment information	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	6,191	2,141	'
Income (loss) before income taxes	'	'	'	'	'	'	'	'	5,307	3,770	'
Depreciation and amortization	'	'	'	'	'	'	'	'	551	428	'
Corporate and Other	'	'	'	'	'	'	'	'	'	'	'
Segment information	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	-6,191	-2,141	'
Income (loss) before income taxes	'	'	'	'	'	'	'	'	-40,507	-31,717	'
Depreciation and amortization	'	'	'	'	'	'	'	'	$3,457	$2,815	'

Legal_Proceedings_Details

Legal Proceedings (Details) (USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	8-May-12	Jan. 31, 2014	Jan. 31, 2014
	CardioNet v. ScottCare Litigation	Litigation settled	Litigation settled
	patent	CardioNet v. Mednet Litigation	CardioNet v. Mednet Litigation
		Subsequent event	Subsequent event
		patent	Mednet and its affiliated entities
Legal proceedings	'	'	'
Number of patents infringed by the defendants	'	5	'
Cash consideration paid under definitive stock purchase agreement	'	'	$5.50
Shares of common stock issued under definitive stock purchase agreement	'	'	96,649
Assumed outstanding secured debt, including interest under definitive stock purchase agreement	'	'	$10
Number of patents allegedly infringed	5	'	'

Legal_Proceedings_Details_2

Legal Proceedings (Details 2) (USD $)	0 Months Ended
In Thousands, unless otherwise specified	Jun. 12, 2012	Dec. 31, 2013
	Lifewatch	CardioNet, Inc. and Braemar Manufacturing, LLC
Legal proceedings	'	'
Settlement amount paid	$250	'
Accrual of contingent liabilities	'	$0

Civil_Investigative_Demand_Det

Civil Investigative Demand (Details) (Civil Investigative Demand, USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Civil Investigative Demand	'
Civil Investigative Demand	'
Accrual of contingent liabilities	$0

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Data (Unaudited)	'	'	'	'	'	'	'	'	'	'	'
Total revenues	$33,105	$31,874	$32,104	$32,418	$29,959	$27,040	$27,450	$27,045	$129,501	$111,494	$119,022
Gross profit	20,795	19,234	19,496	19,545	17,167	16,398	16,726	15,610	79,070	65,901	69,946
Integration, restructuring and other charges	1,162	3,077	2,541	1,202	2,492	741	733	270	7,982	4,236	4,659
Income (loss) from operations	226	-2,835	-2,238	-2,034	-4,784	-3,126	-1,668	-3,581	-6,881	-13,159	-61,322
Net income (loss)	$23	($2,956)	($2,299)	($2,087)	($4,349)	($3,121)	($1,198)	($3,534)	($7,319)	($12,202)	($61,422)
Basic and diluted net income (loss) per share	$0	($0.12)	($0.09)	($0.08)	($0.17)	($0.12)	($0.05)	($0.14)	($0.29)	($0.49)	($2.51)

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent event, USD $)	Feb. 21, 2014	Feb. 21, 2014	Feb. 21, 2014	Jan. 31, 2014	Jan. 31, 2014
		April 2014 to March 2019	April 2019 to March 2024	Litigation settled	Mednet entities
				CardioNet v. Mednet Litigation	Litigation settled
				patent	CardioNet v. Mednet Litigation
Subsequent events	'	'	'	'	'
Number of patents infringed	'	'	'	5	'
Cash consideration paid under purchase agreement	'	'	'	'	$5,500,000
Shares of common stock issued under purchase agreement	'	'	'	'	96,649
Assumed outstanding secured debt, including interest under purchase agreement	'	'	'	'	10,000,000
Interest rate ( as a percent)	3.25%	'	'	'	'
Principal amount of monthly installment payments	'	$37,500	$75,000	'	'

Schedule_IIValuation_and_Quali1

Schedule II-Valuation and Qualifying Accounts and Reserves (Details) (Allowance for Doubtful Accounts, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for Doubtful Accounts	'	'	'
Allowance for Doubtful Accounts	'	'	'
Beginning Balance	$7,617	$9,889	$11,779
Additions Charged To Expense	7,787	11,912	12,080
Deductions From Reserve	-7,763	-14,184	-13,970
Ending Balance	$7,640	$7,617	$9,889